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The	  colonisation	  of	  the	  infant	  gut	  starts	  prior	  to	  birth	  and	  continues	  throughout	  life.	  Specific	  
factors	  may	  influence	  the	  microbiota	  composition	  in	  infants.	  The	  main	  purpose	  here	  was	  to	  
characterise	   the	   compositional	   development	   of	   the	   gut	   microbiota	   in	   early	   infancy.	   A	  
particular	   focus	   of	   interest	   was	   the	   impact	   of	   specific	   factors	   such	   as	   mother’s	   gut	  
microbiota,	  environment,	  dietary	  habits	  and	  probiotics,	  which	  may	  influence	  this	  process.	  
	  
Maternal	  B.	   bifidum	   and	   B.	   breve	   colonisation	   increased	   the	   infants’	   probability	   of	   being	  
colonised	   by	   these	   species.	   High	  maternal	   levels	   of	   Bifidobacterium	   genus	   and	  B.	   longum	  
correlated	  with	  high	  levels	  of	  the	  same	  bacteria	  in	  infants	  at	  1	  and	  6	  months	  of	  age.	  	  
Gut	   microbiota	   analyses	   of	   infants	   from	   different	   geographical	   locations	   revealed	  
bifidobacteria	  to	  be	  dominant	  at	  6	  months	  of	  age	  in	  Malawian,	  Finnish	  and	  German	  infant	  
populations.	   Distinctions	   were	   related	   to	   differences	   in	   bifidobacteria,	   clostridia,	  
Bacteroides	   and	   Akkermansia,	   between	   Malawian	   and	   Finnish,	   and	   Finnish	   and	   German	  
infants.	   Different	   feeding	   practices	   in	   Malawian	   and	   Finnish	   and	   German	   infants	   had	   an	  
impact	   on	   microbiota	   composition	   and	   development	   in	   infants.	   Maternal	   and	   infant	  
probiotic	  intervention	  with	  specific	  study	  strains	  modulated	  the	  gut	  microbiota	  in	  6-­‐month-­‐
old	  infants.	  The	  properties	  of	  the	  probiotic	  strains	  used	  in	  studies	  on	  human	  subjects	  were	  
altered	   by	   the	   production	   process;	   the	   probiotic	   L.	   rhamnosus	   GG	   isolates	   obtained	   from	  
different	   sources	  of	  probiotic	  products	   showed	  different	  properties	   in	  pathogen	  exclusion	  
from	  the	  mucus.	  
	  
Factors	  such	  as	  maternal	  microbiota,	   infant’s	  diet,	  hygiene	  and	  use	  of	  probiotics	  guide	  the	  
intestinal	   microbiota	   composition	   in	   infants	   and	   this	   may	   have	   an	   impact	   on	   early	  
programming	   for	   later	   health.	   In	   addition,	   the	   quality	   of	   probiotic	   products	   should	   be	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AAD	   	   antibiotic-­‐associated	  diarrhoea	  
Bb12	   	   Bifidobacterium	  lactis	  Bb12	  
BL999	   Bifidobacterium	  longum	  (ATCC:	  
BAA-­‐999)	  
CI	   	   confidence	  interval	  
DI	   	   diversity	  index	  
ERIC-­‐PCR	   enterobacterial	  repetitive	  
intergenic	  consensus-­‐PCR	  
FAO	   	   Food	  and	  Agriculture	  	  
	   	   Organisation	  
FCM-­‐FISH	   flow	  cytometry-­‐FISH	  
FISH	   	   fluorescent	  in	  situ	  hybridisation	  
FOS	   	   fructo-­‐oligosaccharides	  
GALT	   	   gut	  associated	  lymphoid	  tissue	  
GIT	   	   gastrointestinal	  tract	  
GOS	   	   galacto-­‐oligosaccharides	  
IBD	   	   inflammatory	  bowel	  disease	  
IBS	   	   irritable	  bowel	  syndrome	  
IgA	   	   immunoglobulin	  A	  
IQR	   	   interquartile	  range	  
	  
	  
LAB	   	   lactic	  acid	  bacteria	  
LGG	   	   Lactobacillus	  rhamnosus	  GG	  
LPR	   Lactobacillus	  rhamnosus	  (CGMCC	  
1.3724)	  
NEC	   	   necrotising	  enterocolitis	  
PCR	   	   polymerase	  chain	  reaction	  
PFGE	   	   pulsed	  field	  gel	  electrophoresis	  
qPCR	   	   quantitative-­‐PCR	  
RCTs	   	   randomised	  controlled	  trials	  
RAPD	   randomly	  amplified	  polymorphic	  
DNA	  
SCFA	   	   short-­‐chain	  fatty	  acids	  
SD	   	   standard	  deviation	  
SI	   	   similarity	  index	  
ssp.	  	   	   subspecies	  
ST11	   Lactobacillus	  paracasei	  (CNCM	  1-­‐
2116)	  
WHO	   	   World	  Health	  Organisation	  
16S	  rDNA	   ribosomal	  bacterial	  16S	  DNA	  
coding	  gene	  of	  16S	  rRNA	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In	  addition,	  some	  unpublished	  results	  are	  presented.	  
	  
















The	   human	   gastrointestinal	   tract	   is	   the	   home	   of	   a	   vast	   community	   of	   microbes,	   which	  
include	  bacteria,	  viruses	  and	  yeasts.	  Microbes	  are	  spread	  throughout	  the	  gut,	  the	  majority	  
however	  being	  present	  in	  the	  colon.	  These	  indigenous	  microbes	  co-­‐exist	  with	  the	  host	  in	  a	  
beneficial	   mutual	   relationship	   crucial	   for	   the	   maintenance	   of	   health	   at	   all	   stages	   of	   life	  
(Guarner	  and	  Malagelada	  2003).	  
	  
Diet,	  ethnicity,	  sanitation,	  hygiene,	  geography	  and	  climate	  have	  been	  found	  to	  have	  a	  long-­‐
term	  impact	  on	  the	  succession	  of	  microbes	  in	  infants.	  Differences	  in	  microbiota	  composition	  
characterise	  infants	  living	  in	  different	  parts	  of	  the	  world,	  but	  bifidobacteria	  dominate	  in	  the	  
infant	   microbial	   ecosystem	   (Favier	   et	   al.	   2002,	   Fanaro	   et	   al.	   2003).	   Differences	   in	  
bifidobacterial	   composition	   and	   level,	   again,	   may	   appear	   in	   infants	   living	   in	   different	  
countries	  (Fallani	  et	  al.	  2010).	  	  
	  
Aberrancies	  in	  the	  compositional	  development	  of	  the	  microbiota	  have	  been	  documented	  as	  
increasing	   the	   risk	   of	   immunological	   and	   inflammatory	   diseases	   (Kalliomäki	   et	   al.	   2001a,	  
2008)	  both	  in	  children	  and	  in	  adults.	  This	  increase	  may	  in	  part	  be	  attributable	  to	  changes	  in	  
host-­‐microbe	   interactions	   caused	   by	   implementation	   of	   different	   antimicrobial	   strategies	  
(i.e.	   excessive	   use	   of	   antibiotics,	   improved	   hygiene	   and	   Western	   diets).	   Moreover,	   it	   is	  
increasingly	   evident	   that	   gut	   microbes	  may	   influence	   energy	   harvesting	   and	   storage	   and	  
shape	   the	   host	  metabolic	   network,	   thereby	   impacting	   on	   the	   growth	   pattern	   and	   risk	   of	  
obesity	  and	  related	  disorders	  (Ley	  et	  al.	  2006).	  
	  
During	  recent	  years	  beneficial	  bacteria,	  so-­‐called	  probiotics,	  have	  been	  suggested	  to	  play	  an	  
important	  role	  in	  gut	  microbiota	  modulation	  and	  activity.	  Probiotics	  may	  thus	  maintain	  the	  
health	  of	  the	  host,	  contributing	  to	   immune	  function	  and	  defence	  against	  certain	  disorders	  
(Collado	  et	  al.	  2009).	  Specific	  probiotics	  with	  health	  benefits	  are	  selected	  based	  on	  their	   in	  
vitro	   and	   in	   vivo	   properties.	   However,	   such	   properties	   may	   in	   fact	   be	   influenced	   by	   the	  






The	  aim	  of	  the	  present	  work	  was	  to	  characterise	  the	  compositional	  development	  of	  the	  gut	  
microbiota	   in	   early	   infancy,	   in	   particular	   the	   microbial	   link	   between	   mother	   and	   infant	  
during	   the	   perinatal	   period	   and	   the	   role	   of	   diet,	   environment	   and	   specific	   probiotic	   use,	  

































2.	  REVIEW	  OF	  THE	  LITERATURE	  
	  
2.1	  Microbial	  community	  in	  the	  gastrointestinal	  tract	  
	  
The	   condition	  and	   function	  of	   the	  gastrointestinal	   tract	   (GIT)	   are	   crucial	   to	  our	  wellbeing.	  
The	  GIT	   constitutes	  one	  of	   the	   largest	  body	   surface	  areas,	  estimated	   to	  be	  approximately	  
250	  to	  400	  m2	  in	  area	  and	  7	  m	  long	  in	  adults.	  The	  GIT	  harbours	  a	  microbiota	  of	  at	  least	  500-­‐
1000	  different	  bacterial	  species	  comprising	  nearly	  2	  million	  genes.	  It	  is	  populated	  with	  up	  to	  
1014	  microbial	  cells,	  which	  is	  estimated	  to	  be	  10	  times	  the	  number	  of	  human	  cells.	  This	  rich	  
microbiota	  is	  regarded	  as	  an	  active	  “organ”	  of	  the	  human	  body	  (Magalhaes	  et	  al.	  2007,	  Artis	  
et	  al.	  2008,	  Ley	  et	  al.	  2008,	  Zoetendal	  et	  al.	  2008).	  
Recent	   reports	   indicate	   that	   80-­‐90%	   of	   the	   bacterial	   phylotypes	   are	   members	   of	  
Bacteroidetes	  phylum,	   including	  Bacteroides	   and	  Prevotella	  genus,	  and	  Firmicutes	  phylum,	  
including	   Clostridium,	   Enterococcus,	   Lactobacillus	   and	   Ruminococcus	   genus.	   Other	   phyla	  
present	   in	   the	   gut	   belong	   to	   Actinobacteria,	   including	   the	   Bifidobacterium	   genus,	   and	  
Proteobacteria,	   including	  Helicobacter	   and	  Escherichia	   (Eckburg	   et	   al.	   2005,	   Turroni	   et	   al.	  
2008,	  Tap	  et	  al.	  2009).	  
The	   bacteria	   of	   the	   human	   gut	   include	   indigenous	   (native)	   species	   which	   permanently	  
colonise	  the	  GI	  tract,	  and	  a	  variable	  set	  of	   living	  microorganisms	  which	  transit	  temporarily	  
through	  the	  tract.	  The	  indigenous	  bacteria	  are	  mainly	  acquired	  at	  birth	  and	  during	  the	  first	  
years	   of	   life	   and	   have	   sometimes	   been	   classified	   as	   either	   potentially	   harmful	   or	   health-­‐
promoting;	  most	  of	  them,	  however,	  constitute	  part	  of	  the	  commensal	  microbiota.	  Transient	  
bacteria	  are	  continuously	  being	  ingested	  from	  the	  environment,	  this	  including	  food.	  
The	   number	   and	   composition	   of	   microbes	   vary	   along	   the	   GIT	   and	   concomitant	   with	  
environmental	  conditions	  and	  the	  age,	  gender,	  country	  and	  health	  status	  of	   the	  host.	  The	  
dominant	  microbial	  genera	  inhabiting	  the	  human	  GIT	  are	  presented	  in	  Figure	  1.	  The	  mouth	  
is	   colonised	   by	   facultative	   and	   strict	   anaerobes	   including	   streptococci,	   Bacteroides,	  
lactobacilli	   and	   yeasts.	   The	   oesophagus	   has	   no	   microbiota	   of	   its	   own;	   bacteria	   originate	  
from	  the	  oral	  cavity,	  the	  respiratory	  system	  and	  food.	  Microbiota	  numbers	  in	  the	  stomach	  
and	  duodenum	  are	   low	  due	   to	   flow	  and	   low	  pH	   in	   the	   stomach	  and	  secretion	  of	  bile	  and	  
pancreatic	   juice	   in	   the	   duodenum;	   the	   colonisation	   is	   mainly	   represented	   by	   facultative	  
anaerobes	   and	   yeasts.	   The	   resident	   found	   in	   the	   stomach	   is	   Helicobacter	   pylori.	   In	   the	  




jejunum	   and	   ileum	   bacterial	   numbers	   gradually	   increase,	   reaching	   their	   highest	   level	   and	  
diversity	  in	  the	  colon.	  The	  microbiota	  of	  the	  jejunum	  and	  ileum	  is	  represented	  by	  facultative	  
anaerobes	   and	   anaerobes.	   The	   majority	   of	   species	   in	   the	   colon	   are	   obligate	   anaerobic	  
microorganisms	  forming	  a	  complex	  and	  dynamic	  ecosystem	  (Bik	  2009,	  Tan	  et	  al.	  2011).	  
The	   gut	   microbiota	  may	   exist	   in	   the	   lumen	   or	   be	   associated	   with	   the	   intestinal	   mucosa,	  
forming	   a	   biofilm.	  Bacteroides,	   Eubacterium,	  Bifidobacterium,	   Lactobacillus,	  Gram-­‐positive	  
cocci	   and	   Clostridium	   represent	   lumenal	   (planktonic)	   bacteria,	   whose	   number	   and	  
composition	   are	   affected	   by	   the	   diet.	   The	   mucosally-­‐associated	   bacteria,	   for	   example	  
Bacteroides,	  Fusobacterium,	  Spirochaetes,	  E.	   coli,	  Helicobacter,	  Bifidobacterium	  and	  Gram-­‐
positive	   cocci,	   are	   less	   affected	   by	   the	   diet,	   remain	   more	   stable	   and	   have	   the	   ability	   to	  
regulate	  the	  lumenal	  bacteria	  (Probert	  and	  Gibson	  2002,	  Ouwehand	  et	  al.	  2004).	  	  
	  
Figure	  1.	  The	  human	  gastrointestinal	  tract	  and	  its	  dominant	  microbial	  genera	  (modified	  after	  Ouwehand	  and	  
Vesterlund	  2003).	  
	  
The	   gastrointestinal	   tract	   is	   covered	   by	   epithelial	   cells	   and	   mucus,	   which	   form	   a	   barrier	  
between	  the	  external	  and	  internal	  environment	  of	  the	  human	  body.	  The	  mucus	  is	  a	  viscous	  
gel	   composed	   mainly	   of	   high-­‐molecular-­‐mass-­‐glycoproteins	   called	   mucins;	   water,	   lipids,	  




other	  proteins	  and	  salts.	  The	  mucus	  layer	  has	  a	  very	  large	  surface	  area	  (300	  m2)	  forming	  an	  
ecological	  niche	  for	  intestinal	  microbiota.	  The	  major	  function	  of	  the	  mucus	  is	  to	  protect	  the	  
epithelial	  cells	   from	  damage	  caused	  by	  chemical,	  enzymatic	  and	  mechanical	  activity	   in	  the	  
GIT.	   The	   mucus	   also	   forms	   a	   barrier	   to	   protect	   the	   underlying	   epithelium	   from	   the	  
attachment	  of	  pathogens	  and	  serves	  as	  a	  source	  of	  nutrients	  for	  some	  commensal	  bacteria	  
such	   as	  Bacteroides	   and	  Akkermansia	   (Salyers	   et	   al.	   1988,	  Guarner	   and	  Malagelada	  2003,	  
Derrien	  et	  al.	  2004).	  
The	   activity	   of	   the	   intestinal	   microbiota	   is	   high,	   involving	   metabolic	   processes	   such	   as	  
fermentation	  of	   exogenous	   and	  endogenous	   carbon	   and	  energy	   sources.	   Fermentation	  of	  
different	  oligosaccharides	  results	  in	  the	  production	  of	  short-­‐chain	  fatty	  acids	  (SCFA),	  which	  
provide	   the	   host	   with	   additional	   energy	   and	   maintain	   mucosal	   health	   (Mortensen	   and	  
Clausen	   1996).	   Some	   members	   of	   the	   intestinal	   microbiota,	   for	   example	   bifidobacteria,	  
lactobacilli	  and	  Bacteroides	  are	  involved	  in	  the	  production	  of	  vitamins	  B	  and	  K	  (Strozzi	  and	  
Mogna	  2008).	  Additionaly,	   intestinal	  microbes	   are	   able	   to	  utilise	  other	   substrates	   such	   as	  
proteins	  and	  amino	  acids,	  which	  may	  lead	  to	  the	  production	  of	  a	  variety	  of	  toxic	  substances	  
such	  as	  tumour	  inducers.	  The	  intestinal	  microbiota	  is	  considered	  an	  important	  constituent	  in	  
the	   mucosal	   defence	   barrier.	   It	   provides	   protection	   against	   incoming	   microbes	   via	  
competition	  for	  the	  same	  attachment	  sites	  as	  these,	  uses	  the	  same	  nutrients	  as	  pathogens,	  
and	   produces	   numerous	   compounds	   inhibiting	   the	   growth	   of	   undesirable	   bacteria	  
(Magalhaes	  et	  al.	  2007).	  The	  gut	  microbiota	  also	  stimulates	  the	  maturation	  of	  the	  immune	  
system.	  Exposure	  to	  microbes	  increases	  the	  number	  of	  specific	  immune	  components,	  which	  
promote	  the	  immunological	  barrier	  of	  the	  gut	  mucosa	  (Grönlund	  et	  al.	  2000).	  
	  
	  
2.2	  Development	  of	  gut	  microbiota	  
	  
The	  newborn	  child	  is	  continuously	  exposed	  to	  new	  environmental	  microbes	  which	  enter	  the	  
gastrointestinal	  tract	  with	  food	  and	  drink	  (Figure	  2).	  
The	  development	  of	  the	  gut	  microbiota	  passes	  through	  the	  different	   life	  stages,	  especially	  
infancy	  and	  weaning.	  
	  
	  






The	  gastrointestinal	  tract	  of	  a	  foetus	  has	  been	  generally	  considered	  microbiologically	  sterile,	  
but	   there	   are	   indications	   of	   exposure	   to	   bacteria	   already	   prior	   to	   delivery	   (Jiménez	   et	   al.	  
2005,	  Onderdonk	  et	  al.	  2008,	  Satokari	  et	  al.	  2009).	  
After	   birth,	   the	   infant	   gut	   begins	   to	   be	   gradually	   colonised	   by	   a	   rapidly	   diversifying	  
microbiota.	  The	  first	  microbes	  to	  colonise	  are	  facultative	  anaerobes	  such	  as	  enterobacteria,	  
coliforms,	   lactobacilli	   and	   streptococci,	   followed	   on	   the	   2nd-­‐3rd	   day	   by	   anaerobes	   such	   as	  
bifidobacteria,	   Bacteroides,	   clostridia	   and	   eubacteria	   as	   the	   main	   microorganisms	   in	   1-­‐2-­‐
week-­‐old	   infant	   faeces	   (Benno	   and	  Mitsuoka	   1986,	   Park	   et	   al.	   2005).	  Molecular	  methods	  
have	   also	   demonstrated	   the	   presence	   of	   other	   types	   such	   as	   Ruminococcus	   and	  
Akkermansia-­‐like	  bacteria	  at	  an	  early	  stage	  in	  the	  infant	  gut	  (Favier	  et	  al.	  2002,	  Collado	  et	  al.	  
2007a).	  
The	  most	  common	  bifidobacteria	  present	   in	   infant	  faeces	  are	  B.	   longum,	  B.	   infantis	  and	  B.	  
breve	  (Roger	  et	  al.	  2010).	  Among	  lactobacilli	  the	  most	  abundant	  species	  found	  are	  L.	  gasseri	  
and	  L.	  johnsonii,	  both	  belonging	  to	  the	  L.	  acidophilus	  group	  (Morelli	  et	  al.	  1998).	  
	   	  
Figure	  2.	  The	  establishment	  of	  the	  gut	  microbiota	  –	  a	  step-­‐wise	  process	  (modified	  after	  Benno	  and	  Mitsuoka	  
1986).	  




2.2.2	  Early	  life	  
	  
After	  the	  first	  6	  months	  of	  life,	  when	  solid	  food	  is	  introduced	  to	  the	  diet,	  the	  gut	  microbiota	  
becomes	   more	   diverse.	   The	   succession	   of	   Bacteroides,	   Clostridium	   and	   anaerobic	   cocci	  
increases	   rapidly	   while	   the	   proportion	   of	   bifidobacteria	   decreases	   and	   becomes	   more	  
stable.	  The	  changes	   in	  microbiota	  composition	  during	  weaning	  are	  more	  drastic	   in	  breast-­‐
fed	   than	   in	   formula-­‐fed	   infants.	   After	   weaning	   the	   gut	   microbiota	   continues	   to	   develop	  
towards	  the	  adult	  status	  and	  after	  2	  years	  of	  age	  the	  composition	  is	  practically	  identical	  to	  
that	  of	  an	  adult	  (Magne	  et	  al.	  2006,	  Morelli	  2008).	  
	  
	  
2.3	  Factors	  affecting	  gut	  microbiota	  development	  and	  composition	  in	  infants	  
	  
Microbiota	   development	   in	   the	   infant	   is	   rapid	   and	   depends	   on	   the	   first	   inoculum,	   the	  
mother’s	   microbiota,	   mode	   of	   delivery,	   type	   of	   feeding	   and	   the	   environment,	   including	  
weaning	   food	   practices	   and	   the	   use	   of	   antimicrobials	   (Figure	   2),	   (Favier	   et	   al.	   2002,	  
Adlerberth	  and	  Wold	  2009).	  
	  
Maternal	  microbiota	  
It	   has	   been	   hypothesised	   that	   the	   maternal	   intestinal	   bacteria	   or	   their	   components	   are	  
present	   in	  the	  placenta	  and	  that	  the	  foetus	  may	  be	  exposed	  to	  them.	  Recent	  studies	  have	  
shown	   that	   horizontal	   transfer	   of	   bacterial	   DNA	   from	   mother	   to	   foetus	   may	   occur	   via	  
placenta	  (Satokari	  et	  al.	  2009).	  
In	   a	   study	   conducted	   by	   Gueimonde	   and	   collaborators	   (2006)	   administration	   of	   specific	  
probiotics	  to	  the	  mothers	  during	  pregnancy	  was	  seen	  to	  influence	  microbiota	  establishment	  
in	   newborn	   infants.	   This	   suggests	   that	   specific	   changes	   in	   the	   transfer	   and	   initial	  
establishment	  of	  microbiota	  in	  neonates	  take	  place	  as	  a	  consequence	  of	  the	  consumption	  of	  
probiotics	  by	  the	  mothers.	  
	  
Mode	  of	  delivery	  
The	  mode	  of	  delivery	  has	  a	  significant	  effect	  on	  the	  microbial	  colonisation	  of	  the	  infant	  gut.	  
Vaginally	   delivered	   infants	   come	   into	   contact	   with	   the	   maternal	   vaginal	   and	   faecal	  




microbiota.	  This	  results	  in	  gut	  colonisation	  by	  microbes	  originating	  from	  the	  mother’s	  birth	  
canal.	   The	   maternal	   gut	   is	   the	   most	   important	   source	   of	   E.	   coli,	   bifidobacteria	   and	  
Bacteroides	   in	   the	  early	   colonisation	  of	   the	   infant	   gut.	   Colonisation	  with	   these	  bacteria	   is	  
delayed	   in	   infants	  born	  by	  caesarean	  section.	  These	   infants	  are	  more	  often	  colonised	  with	  
clostridia	  and	   less	  with	  bifidobacteria	  and	   lactobacilli	   (Grönlund	  et	  al.	  1999,	  Penders	  et	  al.	  
2006,	  Marques	  et	  al.	  2010).	  	  
	  
Type	  of	  feeding	  
The	  type	  of	  feeding,	  together	  with	  the	  above-­‐mentioned	  mode	  of	  delivery,	  exert	  the	  most	  
significant	   influences	   on	   the	   development	   of	   the	  microbiota	   in	   the	   infant.	   The	   preferred	  
food	  for	  the	  infant	  is	  breastmilk,	  which	  in	  healthy	  mothers	  contains	  from	  105	  to	  109	  bacteria	  
per	  mL	  (Morelli	  2008).	  Breast-­‐feeding	  is	  strongly	  recommended,	  as	  many	  protective	  factors	  
are	  transmitted	  via	  breastmilk.	  Breastmilk	  delivers	  numerous	  bioactive	  components	  to	  the	  
infant’s	  gut,	  which	  influence	  microbial	  colonisation	  and	  maturation	  of	  the	  intestinal	  mucosa	  
and	  immune	  system.	  Breastmilk	  is	  also	  an	  important	  source	  of	  bifidobacteria	  and	  lactic	  acid	  
bacteria,	  which	  further	  facilitate	  the	  impact	  of	  the	  mother	  in	  gut	  colonisation	  of	  the	  infant	  
(Gueimonde	  at	  al.	  2007,	  ESPGHAN	  2009,	  Beattie	  and	  Weaver	  2011).	  
The	  intestinal	  microbiota	  of	  healthy	  breast-­‐fed	  infants	  is	  composed	  mainly	  of	  bifidobacteria	  
(Grönlund	  et	  al.	  2007,	  Roger	  et	  al.	  2010),	  which	  may	  reach	  up	  to	  60-­‐90%	  of	  the	  total	  faecal	  
microbiota	   (Favier	   et	   al.	   2002).	   Other	   microbes	   include	   Staphylococcus,	   Streptococcus,	  
Corynebacterium,	   Lactobacillus,	   Micrococcus	   and	   Propionibacterium,	   originating	   from	   the	  
nipple,	  milk	  ducts	  and	  the	  surrounding	  skin.	  	  
The	   profile	   of	   formula-­‐fed	   infants	   is	   more	   complex	   and	   similar	   to	   that	   of	   adults,	  
predominant	   facultative	   anaerobes	   being	   Bacteroides	   and	   Clostridium,	   followed	   by	  
Staphylococcus,	   Streptococcus	   and	   Enterobacteriaceae.	   Colonisation	   by	   bifidobacteria	   is	  
delayed	   (Matsuki	   et	   al.	   1999,	   Harmsen	   et	   al.	   2000,	   Grönlund	   et	   al.	   2007,	  Marques	   et	   al.	  
2010).	   The	   target	   of	   infant	   formula	   research	   has	   been	   to	   develop	   formulas	   to	   closely	  
resemble	  breastmilk	  (Rinne	  et	  al.	  2005).	  
	  
Lifestyle	  
Lifestyle,	   comprising	   such	   factors	   as	   family	   structure	   and	  home	  environment,	  may	  have	   a	  
significant	   impact	   on	   gut	   microbiota	   composition.	   A	   recent	   study	   reports	   that	   infants	  




without	  older	  siblings	  have	  more	  non-­‐E.	  coli	  enterobacteria	  and	  clostridia	  and	  a	  lower	  ratio	  
of	  anaerobic	   to	   facultative	  bacteria	  by	  one	  year	  of	  age	  compared	  to	  children	  with	  siblings	  
(Adlerberth	  et	  al.	  2007).	  In	  another	  study,	  conducted	  by	  Penders	  and	  collaborators	  (2006),	  
single	  children	  tended	  to	  have	  lower	  counts	  of	  bifidobacteria	  in	  the	  gut	  at	  one	  month	  of	  age	  
than	   infants	   with	   older	   siblings.	   A	   recent	   study	   conducted	   by	   Ege	   and	   coworkers	   (2011)	  
shows	   that	   children	   living	  on	   farms	  are	  exposed	   to	  a	  wider	   range	  of	  microbes	   than	   those	  
who	   are	   not	   living	   on	   farms.	   This	   would	   suggest	   a	   more	   mature	   colonisation	   pattern	   in	  




Several	   groups	  have	   reported	   that	   geographic	   location	  may	  affect	   the	   composition	  of	   the	  
gut	   microbiota.	   A	   recent	   study	   conducted	   by	   Fallani	   and	   coworkers	   (2010)	   shows	   a	  
“geographical	   gradient“	   in	   the	   microbiota	   composition	   across	   young	   Europeans.	   The	   6-­‐
week-­‐old	   infant	   faeces	   from	   northern	   European	   locations	   (Glasgow	   and	   Stockholm)	  
contained	   higher	   proportions	   of	   Bifidobacterium,	   Atopobium,	   Clostridium	   perfringens,	   C.	  
difficile	   than	   in	   infants	   from	   the	   south	   (Granada	   and	   Reggio	   Emilia)	   at	   the	   same	   age,	  
containing	   higher	   proportions	   of	   Bacteroides,	   Eubacterium	   and	   Lactobacillus.	   Based	   on	  
numerous	  reports,	   it	  seems	  that	  geographical	  differences	   in	  microbiota	  composition	  result	  
from	  different	  dietary	  habits	   in	   the	  region	  or	  country	   in	  question.	   In	  a	   recent	  study	  by	  De	  
Filippo	   and	   collaborators	   (2010),	   again,	   it	   was	   demonstrated	   that	   children	   living	   in	   rural	  
villages	   in	   Burkina	   Faso	   are	   characterised	   by	   an	   enrichment	   of	   Bacteroides	   as	   against	  
Enterobacteriaceae	   in	   Italian	   children.	   It	   is	   noteworthy	   that	   the	  above-­‐mentioned	  Burkina	  
Faso	  subjects	  were	  characterised	  by	  a	  higher	   intake	  of	  dietary	   fibre	  such	  as	  GOS	   (galacto-­‐
oligosaccharides)	   and	   FOS	   (fructo-­‐oligosaccharides)	   in	   their	   diet,	   which	   may	   have	  
significantly	   guided	   microbiota	   composition.	   Differences	   in	   microbiota	   composition	   have	  
also	   been	   reported	   between	   infants	   from	   two	   northern	   European	   countries.	   Sepp	   and	  
coworkers	   (1997)	   found	  high	  counts	  of	   lactobacilli,	  eubacteria	  and	  enterococci	   in	  Estonian	  








Dietary	  strategies:	  antibiotics,	  probiotics	  and	  prebiotics	  
The	  development	  of	  the	  infant’s	  gut	  microbiota	  can	  be	  influenced	  by	  the	  use	  of	  antibiotics,	  
probiotics	  and	  prebiotics,	  which	  can	  shape	  the	  microbiota	  composition.	  Antibiotics	  are	  very	  
commonly	  used	  to	  treat	  specific	  infections,	  often	  however	  without	  considering	  their	  impact	  
on	  the	  gut.	  Antimicrobials	  are	  not	  only	  selective	  for	  pathogens,	  but	  fundamentally	  affect	  all	  
members	   of	   the	   commensal	   gut	   microbial	   ecosystem,	   especially	   reducing	   the	   levels	   of	  
anaerobic	   bacteria,	   Bacteroides,	   E.	   coli	   and	   beneficial	   bifidobacteria,	   and	   increasing	   the	  
levels	  of	  potentially	  harmful	   clostridia	  and	  Klebsiella	   (Penders	  et	  al.	  2006).	   Infants	   treated	  
with	   antibiotics	   during	   hospitalisation	   may	   develop	   complications	   such	   as	   antibiotic-­‐
associated	  diarrhoea	  (AAD).	  Such	  symptoms	  may	  be	  due	  to	  the	  disturbances	  in	  the	  intestinal	  
microbiota	  composition	  and	  activity	  followed	  by	  an	  overgrowth	  and	  adhesion	  of	  pathogens	  
such	  as	  C.	  difficile	  on	  the	  intestinal	  epithelium	  (McFarland	  1998,	  Sun	  et	  al.	  2011).	  	  
Probiotics	  and	  prebiotics	  have	  been	  proved	  to	  beneficially	  modulate	  the	  gut	  microbiota	  and	  
restore	   the	   disturbed	   microbial	   ecosystem	   after	   antibiotic	   therapy	   (Sartor	   2004,	  
Engelbrektson	  et	  al.	  2009).	  
	  
Other	  factors	  
The	   bacterial	   composition	   in	   the	   gut	  may	   also	   be	   affected	   by	   other	   factors	  which	   in	   fact	  
conceivably	   play	   a	   role	   in	   the	   development	   of	   the	   gut	   microbiota.	   Gestational	   age	   or	  
whether	   the	   birth	   was	   full-­‐	   or	   pre-­‐term	   have	   been	   found	   to	   have	   a	   prominent	   role	   in	  
determining	  the	  colonisation	  of	  the	  gut	  (Penders	  et	  al.	  2006).	  If	  infants	  are	  separated	  from	  
their	  mothers	  for	  long	  periods	  after	  birth,	  being	  for	  example	  hospitalised,	  the	  environment	  
becomes	  an	  important	  source	  of	  colonising	  bacteria	  (Murono	  et	  al.	  1993,	  Savino	  et	  al.	  2011).	  
Other	  factors	  include	  pH	  in	  the	  stomach,	  peristaltis	  in	  the	  intestines,	  the	  gut	  immune	  system	  
and	  stress	  (Kirjavainen	  and	  Gibson	  1999,	  Hawrelak	  and	  Myers	  2004).	  
	  
	  
Taken	   together,	   the	   basis	   of	   a	   healthy	   gut	  microbiota	   lies	   in	   early	   infancy	   and	   the	   initial	  
process	   of	   intestinal	   colonisation,	   this	   forming	   an	   important	   prerequisite	   for	   later	   health.	  
The	  original	  inoculum	  and	  early	  feeding	  are	  thus	  of	  interest	  in	  defining	  early	  development.	  
Furthermore,	  such	  development	  should	  be	  compared	  in	  different	  countries.	  
	  




2.4	  Host-­‐microbe	  interactions	  
	  
2.4.1	  Host-­‐microbe	  cross-­‐talk	  
	  
At	   birth,	   the	   immune	   system	   is	   immature	   and	   develops	   upon	   exposure	   to	  microbes.	   The	  
intestinal	  microbiota	  has	  a	  significant	  impact	  on	  the	  intestinal	  mucosal	  barrier	  function	  and	  
intestinal	   maturation.	   It	   is	   also	   necessary	   for	   full	   development	   of	   the	   body’s	   largest	  
collection	  of	  lymphoid	  tissue,	  the	  gut-­‐associated	  lymphoid	  tissue	  (GALT)	  (Vael	  and	  Desager	  
2009).	   The	   initial	   neonatal	  microbial	   colonisers	   are	   also	   important	   in	   stimulating	   immune	  
development.	   It	   has	   been	   shown	   that	   the	   absence	   of	   early	  microbial	   stimuli	   in	   germ-­‐free	  
mouse	   models	   causes	   defects	   in	   intestinal	   barrier	   function	   and	   reduced	   inflammatory	  
responses	   (Sudo	   et	   al.	   1997,	   Sellon	   et	   al.	   1998).	   Inoculation	   of	   germ-­‐free	   mice	   with	   an	  
intestinal	  microbiota	  leads	  on	  the	  other	  hand	  to	  a	  rapid	  expansion	  of	  the	  immune	  system.	  
The	   maintenance	   of	   immune	   homeostasis	   takes	   place	   through	   the	   constant	   interactions	  
between	   commensal	   bacteria	   in	   the	   intestinal	   lumen	  and	   the	  epithelial	   and	   immune	   cells	  
within	  the	  gut.	  
Probiotic	   bacteria	   are	   able	   to	   modulate	   immune	   responses,	   enhance	   epithelial	   barrier	  
function	   and	   inhibit	   pathogen	   growth.	   The	   immunomodulatory	   properties	   of	   commensal	  
bacteria	   and	   probiotics	   appear	   to	   be	   markedly	   bacteria-­‐specific	   and	   environment-­‐
dependent	  (Christensen	  et	  al.	  2002,	  Perdigon	  et	  al.	  2002).	  
	  
	  
2.4.2	  Bacterial	  adhesion	  and	  interaction	  with	  pathogens	  
	  
Adherence	  of	  bacteria	  to	  the	  intestinal	  mucus	  is	  known	  to	  be	  a	  prerequisite	  for	  colonisation	  
and	   infection	  of	  the	  gastrointestinal	   tract	  by	  many	  pathogens.	  Adhesion	   is	  also	  one	  of	  the	  
bacterial	  virulence	  factors	  (Finlay	  and	  Falkow	  1997,	  Juntunen	  et	  al.	  2001).	  The	  mechanism	  of	  
adhesion	  is	  complex	  and	  involves	  interactions	  between	  microbe	  and	  surface.	  The	  structures	  
responsible	   for	   bacterial	   adhesion,	   adhesins	   (for	   example	   flagella,	   fimbriae,	   and	   cell	   wall	  
proteins,	   carbohydrates	   and	   lipoteichoic	   acids),	   are	   associated	   with	   the	   cell	   surface	   and	  
have	   been	   suggested	   to	   be	   involved	   in	   the	   adhesion	   of	   bacteria	   to	   intestinal	   surfaces.	  




Adhesins	   have	   the	   ability	   to	   recognise	   oligosaccharide	   residues	   of	   glycoproteins	   or	  
glycolipids	  on	  the	  surface	  of	  host	  cells	  (MacKenzie	  et	  al.	  2009).	  	  
The	  attachment	  of	  bacteria	  to	  intestinal	  surfaces	  is	  mediated	  by	  numerous	  factors,	  including	  
those	  related	  to	  gastrointestinal	  conditions	  such	  as	  pH,	  digestive	  enzymes	  and	  the	  presence	  
of	  bile,	  calcium,	  magnesium	  and	  zinc,	  and	  the	  mucin	  concentration	  (Ouwehand	  et	  al.	  2001a,	  
Ouwehand	  and	  Salminen	  2003,	  Lahtinen	  and	  Ouwehand	  2009,	  Sanchez	  et	  al.	  2010).	  Also	  the	  
age	   and	   the	   health	   status	   of	   the	   host	   both	   affect	   the	   adhesive	   potential	   of	   bacteria	  
(Ouwehand	  et	  al.	  1999,	  He	  et	  al.	  2001a,	  b).	  
	  
The	   adhesion	   of	   probiotics	   to	   intestinal	   surfaces	   has	   been	   widely	   studied.	   Adherent	  
probiotic	   strains	  may	   at	   least	   temporarily	   colonise	   the	   gastrointestinal	   tract	   and	   compete	  
with	  pathogens	  for	  binding	  sites	  (Vesterlund	  et	  al.	  2006).	  Several	  reports	  have	  described	  the	  
inhibitory	   effects	   of	   probiotic	   strains	   on	  model	   pathogen	   adhesion	   to	   the	   human	  mucus	  
(Ouwehand	  et	  al.	  2001b,	  Collado	  et	  al.	  2007c,	  e).	  
The	   ability	   to	   inhibit	   the	   adhesion	   of	   pathogens	   by	   probiotics	   shows	   high	   specificity	   and	  
depends	  on	  both	   the	  probiotic	   and	   the	  pathogen	   strains.	   It	   has	  been	   recognised	   that	   the	  
exclusion	   of	   pathogens	   is	   never	   related	   to	   the	   adhesive	   ability	   of	   the	   probiotic	   tested	  
(Bibiloni	   et	   al.	   1999,	   Collado	   et	   al.	   2009).	   Also	   different	   mechanisms	   are	   involved	   in	   the	  






Currently,	   a	   probiotic	   is	   defined	   as	   a	   “live	   microorganism	   which	   when	   administered	   in	  
adequate	  amounts	  confers	  a	  health	  benefit	  on	  the	  host”	  (FAO/WHO	  2002).	  
	  
Most	  probiotics	  are	  bacteria	  and	  belong	  to	  the	  Lactobacillus	  and	  Bifidobacterium	  genera,	  for	  
example	   Lactobacillus	   rhamnosus,	   L.	   acidophilus,	   L.	   casei,	   L.	   gasseri,	   L.	   reuteri	   and	  
Bifidobacterium	   lactis,	   B.	   longum,	   B.	   breve,	   B.	   bifidum.	   Other	   bacteria	   considered	   as	  
probiotics	   include	   enterococci	   such	   as	   Enterococcus	   faecalis,	   E.	   faecium,	   and	  
propionibacteria	   such	   as	   Propionibacterium	   freudenreichii	   ssp.	   shermanii,	   and	   also	  




Streptococcus	   thermophilus,	   Lactococcus	   lactis,	   Clostridium	   butyricum,	   E.	   coli	   and	   others.	  
Yeasts	   such	   as	   Saccharomyces	   boulardii	   and	   Aspergillus	   oryzae	   are	   also	   regarded	   as	  
probiotics	  (Seki	  et	  al.	  2003,	  Saxelin	  et	  al.	  2005,	  Gupta	  and	  Garg	  2009).	  
Lactobacilli	  and	  bifidobacteria	  are	  Gram-­‐positive,	  non-­‐motile,	  non-­‐spore	  forming,	  catalase-­‐
negative	   rods.	   Lactobacilli	   form	   the	  major	  part	  of	   the	   lactic	  acid	  bacteria	   (LAB)	  group	  and	  
comprise	  more	  than	  120	  species.	  As	  members	  of	  LAB,	  they	  produce	  lactic	  acid	  as	  the	  main	  
or	  one	  of	   the	  main	  end	  products	  of	   carbohydrate	  metabolism.	  The	  genus	  Bifidobacterium	  
includes	   29	   species.	   Lactic	   acid	   is	   the	   end	   product	   of	   bifidobacterial	   fermentative	  
metabolism;	   however,	   bifidobacteria	   differ	   from	   LAB	   phylogenetically	   and	   by	   a	   different	  
sugar	  fermentation	  pathway	  (Axelsson	  1998,	  Tannock	  1999,	  Ballongue	  2004).	  
	  
	  
2.5.1	  Selection	  criteria	  and	  safety	  assessment	  
	  
The	  guidelines	  for	  the	  evaluation	  and	  selection	  of	  probiotics	  for	  food	  use	  were	  established	  
by	   the	   Food	   and	   Agriculture	  Organisation	   of	   the	   United	  Nations	   (FAO)	   and	  World	   Health	  
Organisation	  (WHO)	  groups	  in	  2002	  (FAO/WHO	  2002).	  
It	   was	   established	   that	   probiotics	   should	   be	   characterised	   up	   to	   strain	   level,	   as	   probiotic	  
effects	  are	  strain-­‐specific.	   Identification	  of	  a	  strain	  should	   link	   it	   to	  a	  specific	  health	  effect	  
and	  enable	  accurate	  surveillance	  and	  epidemiological	  studies.	  
It	  was	   recommended	   that	   a	   probiotic	   strain	   should	   be	   identified	   by	   the	  most	   up-­‐to-­‐date,	  
valid	   methodology	   such	   as	   combination	   of	   phenotypic	   and	   genotypic	   tests,	   and	   that	   all	  
strains	  should	  be	  deposited	  in	  an	  internationally	  recognised	  culture	  collection.	  
	  
Hitherto,	   specific	   probiotics	   have	   been	   selected	   and	   characterised	   based	   on	   their	   in	   vitro	  
properties,	  for	  example	  tolerance	  to	  gastrointestinal	  conditions	  (resistance	  to	  gastric	  acidity,	  
bile	   acid	   resistance),	   adhesion	   to	   the	   intestinal	  mucus	   or	   epithelial	   cells	   and	   competitive	  
exclusion	   of	   target	   pathogens,	   bile	   salt	   hydrolase	   activity	   and	   resistance	   to	   spermicides	  
(applicable	  to	  probiotics	  for	  vaginal	  use)	  (Tuomola	  et	  al.	  2001,	  FAO/WHO	  2002,	  Ouwehand	  
et	  al.	  2002,	  Collado	  et	  al.	  2007d).	  
The	  efficacy	  of	  probiotics	  for	  humans	  should	  be	  proved	  in	  human	  trials	  and	  benefits	  should	  
be	  	  reflected	  	  in	  	  improvements	  	  in	  	  condition,	  	  symptoms,	  	  signs,	  	  well-­‐being	  	  or	  	  quality	  	  of	  




life,	   reduced	   risk	   of	   disease	   or	   longer	   time	   to	   next	   occurrence,	   or	   faster	   recovery	   from	  
illness.	  
Standard	   methods	   for	   clinical	   evaluations	   involve	   4	   phases:	   Phase	   1	   is	   concerned	   with	  
safety,	   Phase	   2	   efficacy	   (form	   of	   randomised,	   double-­‐blind,	   placebo-­‐controlled	   design,	  
measuring	   efficacy	   compared	   with	   placebo;	   also	   assesses	   adverse	   effects),	   Phase	   3	  
effectiveness	  and	  Phase	  4	  surveillance	  (FAO/WHO	  2002).	  
	  
The	  use	  of	  probiotics	  has	   increased	  significantly;	  new	  and	  more	  effective	  probiotic	   strains	  
are	  constantly	  appearing	  on	  the	  market.	  It	  is	  recommended	  that	  probiotic	  foods	  be	  properly	  
labeled	  with	  strain	  designation,	  minimum	  numbers	  of	  viable	  bacteria	  and	  the	  end	  of	  shelf-­‐
life,	  storage	  conditions	  and	  manufacturer’s	  contact	  details,	  and	  importantly	  –	  health	  claim(s)	  
(FAO/WHO	  2002).	  However,	  numerous	  probiotic	  products	  available	  on	  the	  market	  lack	  this	  
information.	  
	  
In	  general,	  both	  LAB	  and	  bifidobacteria	  have	  a	  good	  safety	  record;	  since	  they	  are	  present	  in	  
the	  normal	   intestinal	  microbiota	  of	  humans	  and	  have	  a	   long	  history	  of	   safe	  use,	   they	  are	  
rarely	  associated	  with	  side-­‐effects	  (Ishibashi	  and	  Yamazaki	  2001).	  
It	  is	  of	  importance	  for	  novel	  probiotic	  strains	  to	  have	  their	  safety	  ensured	  and	  conform	  to	  all	  
local	   regulations.	   The	   safety	   evaluation	   procedures	   proposed	   by	   FAO/WHO	   (2002)	  
recommend	  that	  probiotic	  strains	  be	  characterised	  by	  the	  following	  tests:	  
	  
1. Determination	  of	  antibiotic	  resistance	  patterns	  
2. Assessment	  of	  certain	  metabolic	  activities	  
3. Assessment	  of	  side-­‐effects	  during	  human	  studies	  
4. Post-­‐market	  monitoring	  
5. If	   the	   strain	  being	  evaluated	  belongs	   to	  a	   species	  known	   to	  produce	  a	  mammalian	  
toxin	  or	  to	  have	  haemolytic	  potential,	  it	  must	  be	  tested	  for	  these	  characteristics.	  
	  
Probiotics	   may	   theoretically	   exert	   a	   variety	   of	   side-­‐effects	   such	   as	   infections,	   metabolic	  
effects,	  adverse	   immunological	  events,	  gene	  transfer,	  and	  antibiotic	   resistance	   (FAO/WHO	  
2002,	  Marteau	  and	  Shanahan	  2003).	  Reports	  of	  bacteriaemia	   involving	  bifidobacteria	  or	  L.	  
rhamnosus	   GG	   are	   rare	   (Salminen	   et	   al.	   2002,	   Mahlen	   and	   Clarridge	   2009,	   Whelan	   and	  




Myers	  2010).	  If	  infection	  has	  occurred	  and	  L.	  rhamnosus	  GG	  has	  been	  found,	  the	  subject	  has	  
always	  been	  predisposed	  to	  infection	  by	  surgical	  trauma	  or	  underlying	  health	  disorders	  and	  
the	   probiotics	   have	   formed	   part	   of	   a	   mixed	   culture	   bacteriaemia	   involving	   other	   benign	  
commensal	   bacteria.	   However,	   there	   are	   reports	   showing	   other	   lactobacilli	   and	   also	  
Saccharomyces	  to	  have	  been	  involved	  in	  several	  onset	  of	  bacteriaemia	  (Mackay	  et	  al.	  1999,	  
Salminen	   et	   al.	   2004)	   and	   fungaemia	   (Hennequin	   et	   al.	   2000)	   infection,	   but	   these	   have	  
occurred	   in	   groups	   of	   patients	   whose	   conditions	   predisposed	   them	   to	   opportunistic	  
infections.	   So	   far	   no	   negative	   side-­‐effects	   of	   probiotics	   have	   been	   reported	   in	   preterm	  
infants.	  In	  addition,	  in	  Finland,	  for	  example,	  L.	  rhamnosus	  GG	  has	  been	  widely	  used	  in	  very-­‐




2.5.2	  Health	  effect	  of	  probiotics	  
	  
Probiotic	   microorganisms	   may	   act	   directly	   on	   the	   host	   or	   via	   modulation	   of	   the	   host	  
intestinal	  microbiota.	  
	  
Documented	   health	   effects	   of	   specific	   probiotics	   have	   been	   obtained	   in	   randomised	  
controlled	   trials	   (RCTs)	   among	   children	   in	   the	   prevention	   and	   treatment	   of	   acute	  
gastroenteritis	   (antibiotic-­‐associated	   diarrhoea,	   rotavirus	   diarrhoea,	   respectively),	  
prevention	  of	  allergy,	  prevention	  of	  necrotising	  enterocolitis	  (NEC)	  in	  very-­‐low-­‐birth-­‐weight	  
infants,	   strenghthening	   of	   the	   immune	   system	   and	   modulation	   of	   the	   immune	   response	  
(Figure	  3).	  
	  
According	   to	   several	   studies,	   specific	   probiotic	   strains	   have	   been	   successful	   in	   the	  
prevention	  and/or	  treatment	  of	  some	  types	  of	  diarrhoea	  in	  children.	  The	  beneficial	  effects	  
have	   resulted	   from	   the	   exclusion	   of	   diarrhoeal	   pathogens	   from	   the	   intestinal	   mucosa,	  
balancing	  the	  commensal	  gut	  microbiota	  and	  modulating	  the	  immune	  response.	  
	  
A	  common	  complication	  during	  antibiotic	  treatment	   is	  antibiotic-­‐associated	  diarrhoea.	  The	  
risk	   factors	   include	  broad-­‐spectrum	  antibiotics,	  host	  physiological	   factors	  and	   the	  hospital	  




environment.	  AAD	  results	   from	  disturbance	  of	  the	   intestinal	  microbiota,	  which	  serves	  as	  a	  
barrier	   to	   opportunistic	   pathogens.	   Based	   on	  meta-­‐analyses	   of	   published	   results	   of	   RCTs,	  
most	  of	  the	  tested	  probiotics,	  for	  example	  Lactobacillus	  rhamnosus	  GG	  (LGG)	  (Szajewska	  et	  
al.	   2006,	   Ruszczyński	   et	   al.	   2008),	   B.	   lactis	   and	   S.	   thermophilus,	   both	   commercial	   strains	  
(Corrêa	   et	   al.	   2005),	   and	   S.	   boulardii,	   (Kotowska	   et	   al.	   2005)	   can	   significantly	   reduce	   the	  
incidence	  of	  AAD	  in	  children.	  
However,	  there	  are	  no	  reports	  on	  RCTs	  among	  children	  treated	  with	  probiotics	  against	  AAD	  
or	  Clostridium	  difficile	  AAD.	  
	  
Acute	  rotavirus	  diarrhoea	  is	  a	  common	  paediatric	  disease	  with	  high	  mortality	  worldwide.	  In	  
several	   RCTs	   it	   has	   been	   shown	   that	   probiotics	   such	   as	   LGG	   (Guandalini	   et	   al.	   2000),	   S.	  
thermophilus	  St065	  (Thibault	  et	  al.	  2004),	  L.	  casei	  DN-­‐114	  001	  (Pedone	  et	  al.	  2000),	  B.	  lactis	  
Bb12	  and	  L.	  reuteri	  ATCC	  55730	  (Weizman	  et	  al.	  2005),	  mixed	  with	  milk	  or	  infant	  formula	  or	  
given	   as	   an	   oral	   supplement,	   are	   effective	   in	   the	   prevention	   of	   acute	   rotavirus	   diarrhea,	  
reducing	  and	  shortening	  the	  episodes	  in	  children.	  
The	  role	  of	  probiotics	  in	  the	  treatment	  of	  acute	  rotavirus	  diarrhoea	  in	  children	  has	  been	  well	  
documented;	  S.	  boulardii	   (Billoo	  et	  al.	  2006)	  and	  LGG	   (Szymański	  et	  al.	  2006)	  have	  yelded	  
positive	  results,	  shortening	  the	  duration	  of	  acute	  rotavirus	  diarrhoea	  in	  children.	  
	  
Atopic	  disorders	  such	  as	  atopic	  eczema,	  allergic	  rhinitis	  and	  asthma	  are	  increasing	  rapidly	  in	  
the	  more	  developed	  countries.	  While	  the	  exact	  aetiology	  is	  unclear,	  environmental	  factors,	  
aberrant	   gut	   microbiota	   composition	   and	   activity,	   impairment	   of	   the	   intestinal	   mucosal	  
barrier	  and	  shift	  of	  the	  Th1/Th2	  –type	  cytokine	  balance	  towards	  a	  Th2	  response	  have	  been	  
shown	  to	  have	  a	  crucial	  role	   in	  the	  development	  of	  allergic	  diseases	  (Guarner	  et	  al.	  2006).	  
Specific	  probiotics	  administered	  to	  allergic	   infants	  are	  effective	  in	  the	  prevention	  of	  atopic	  
eczema	   (Kalliomäki	   et	   al.	   2001b),	   acting	   by	   stabilising	   the	   intestinal	   barrier	   function	   and	  
reducing	  gastrointestinal	   symptoms	   in	  children	  with	  atopic	  diseases	  as	  well	  as	  modulating	  
the	  immune	  system	  (Isolauri	  et	  al.	  2001)	  back	  to	  a	  Th1	  response	  (Isolauri	  2004).	  The	  effect	  
of	   probiotics	   in	   preventing	   atopic	   dermatitis	   has	   been	   demonstrated	   in	   a	   double-­‐blinded	  
RCT	   from	  Finland	  where	  Lactobacillus	   rhamnosus	  GG	  was	  given	   to	  pregnant	   and	   lactating	  
mothers	  who	  had	  a	  marked	  family	  history	  of	  eczema,	  allergic	  rhinitis	  or	  asthma,	  and	  to	  their	  
infants	   for	   the	  first	  6	  months	  after	  birth.	  The	  frequency	  of	  atopic	  dermatitis	  developing	   in	  




the	  offspring	  was	  significantly	  reduced	  by	  2,	  4,	  and	  7	  years	   (Kalliomäki	  et	  al.	  2001b,	  2003,	  
2007).	   In	   a	   study	   conducted	   by	   Kukkonen	   and	   collaborators	   (2007),	   pregnant	   women	  
carrying	   high-­‐risk	   children	   were	   given	   a	   mixture	   of	   4	   probiotic	   strains	   (Lactobacillus	  
rhamnosus	   GG,	   L.	   rhamnosus	   LC705,	   Bifidobacterium	   breve	   Bb99,	   Propionibacterium	  
freudenreichii	  ssp.	  shermanii	  JS)	  before	  delivery	  and	  their	  infants	  subsequently	  received	  the	  
same	   probiotics	   along	   with	   galacto-­‐oligosaccharides	   for	   6	   months	   after	   birth.	   Probiotic	  
treatment	  showed	  no	  effect	  on	  the	  incidence	  of	  allergic	  diseases	  but	  significantly	  prevented	  
eczema	   and	   atopic	   eczema.	   Both	   studies	   conducted	   in	   Finland	   suggest	   an	   inverse	  
association	   between	   atopic	   diseases	   and	   colonisation	   of	   the	   gut	   by	   probiotics.	   Numerous	  
RCTs	  with	  probiotics	  aiming	  at	  the	  prevention	  of	  atopic	  diseases	  have	  failed.	  One	  example	  is	  
a	  study	  conducted	  by	  a	  group	  under	  Kopp	  (2008),	  designed	  on	  a	  protocol	  similar	  to	  that	  of	  
Kalliomäki	  and	  associates	  (2001b)	  but	  demonstrating	  no	  lowered	  cumulative	  risk	  of	  allergic	  
diseases.	  Variation	  in	  the	  outcomes	  of	  clinical	  studies	  may	  result	  from	  host	  factors	  such	  as	  
genetic	  susceptibility,	  microbiota	  composition	  and	  environmental	  factors	  such	  as	  geographic	  
region	  and	  diet,	  and	  study	  variables	  including	  the	  probiotic	  strains	  and	  doses	  used.	  
Probiotics	  have	  not	  yet	  been	  proved	  to	  be	  effective	  in	  the	  treatment	  of	  allergic	  disorders.	  	  
	  
NEC	   is	   the	  most	   common	  gastrointestinal	   emergency	   in	   low-­‐birth-­‐weight	  preterm	   infants.	  
Delayed	   enteral	   feeding,	   frequent	   use	   of	   antibiotic	   therapy	   and	   altered	   acquisition	   of	  
normal	  digestive	  microbiota	  are	  the	  factors	  most	  likely	  contributing	  to	  the	  development	  of	  
NEC	  in	  preterm	  infants.	  Several	  RCTs	  have	  reported	  that	  enteral	  probiotic	  supplementation	  
significantly	   reduced	   the	   incidence	   of	   NEC	   and	   mortality	   among	   premature	   infants.	  
Probiotics	  used	  in	  these	  studies	  have	  included	  LGG	  (Manzoni	  et	  al.	  2006),	  B.	  breve	  YIT	  4010	  
(Kitajima	  et	  al.	  1997),	  S.	  boulardii	  (Costalos	  et	  al.	  2003)	  and	  mixtures	  of	  S.	  thermophilus	  +	  B.	  
infantis	  +	  B.	   bifidum,	  ABC	  Dophilus	   strains	   (Bin-­‐Nun	   et	   al.	   2005)	  and	   L.	   acidophilus	   NCDO	  
1748	  +	  B.	  bifidum	  NCDO	  1453	  (Lin	  et	  al.	  2008).	  
	  
Helicobacter	   pylori	   is	   an	   inhabitant	   of	   the	   stomach	   in	   70-­‐90%	   of	   the	   population	   in	  
developing	  countries	  and	  25-­‐50%	  in	  developed	  countries;	  in	  Finland	  however	  the	  prevalence	  
of	   this	   microorganism	   is	   very	   low	   (Salomaa-­‐Räsänen	   et	   al.	   2010).	   In	   some	   cases	   these	  
bacteria	   may	   become	   harmful	   for	   the	   host,	   causing	   gastric	   and	   duodenal	   ulcers,	   gastric	  
cancer	   and	   other	   gastric	   complications	   (Brown	   2000).	   The	   eradication	   treatment	   includes	  




proton	  pump	  inhibitor	  plus	  at	  least	  two	  antibiotics.	  The	  strain	  Lactobacillus	  casei	  DN-­‐114001	  
has	  a	  high	  success	  rate	  in	  eradicating	  H.	  pylori	  in	  children	  when	  administered	  at	  a	  high	  daily	  
dosage	  of	  1	  x	  1010	  cfu	  (Sykora	  et	  al.	  2005).	  However,	  it	  has	  been	  found	  that	  early	  exposure	  
to	  H.	  pylori,	  particularly	  in	  childhood,	  is	  associated	  with	  a	  lower	  incidence	  of	  allergic	  diseases	  
(Seiskari	  et	  al.	  2007,	  Serrano	  et	  al.	  2011),	  supporting	  the	  hypothesis	  that	  the	  microbial	  load	  
is	   an	   important	   environmental	   factor	   conferring	   protection	   against	   the	   development	   of	  
allergies	  in	  childhood.	  
	  
Figure	  3.	  Suggested	  health	  effects	  and	  new	  challenges	  in	  specific	  probiotic	  strain	  use	  in	  infants.	  
	  
Probiotics	  have	  also	  proved	  efficacious	  in	  the	  treatment	  of	  bowel	  disorders	  such	  as	  irritable	  
bowel	  syndrome	  (IBS)	  and	  inflammatory	  bowel	  disease	  (IBD)	  in	  children.	  
	  
IBS	  includes	  abdominal	  discomfort	  or	  pain,	  diarrhoea,	  constipation,	  bloating	  and	  flatulence,	  
these	  being	  caused	  by	  altered	  gut	  motility,	  visceral	  hypersensitivity	  and	  dysregulation	  of	  the	  
brain-­‐gut	   axis	   (Alaradi	   and	   Barkin	   2002).	   It	   has	   however	   been	   suggested	   that	   IBS	   is	   also	  
caused	   by	   an	   imbalanced	   intestinal	   microbiota	   profile	   and	   enteric	   bacteria-­‐mediated	  




mucosal	  inflammation	  (Bolino	  and	  Bercik	  2010).	  Administration	  of	  specific	  probiotic	  strains	  
can	  however	   relieve	   some	   IBS	   symptoms	   such	  as	   constipation,	   flatulence	  and	  borborygmi	  
(Nobaek	  et	  al.	  2000,	  Koebnick	  et	  al.	  2003).	  One	  RCT	  has	  been	  published	  concerning	  probiotic	  
treatment	  of	  children	  with	  IBS	   in	  which	  LGG	  was	  able	  to	  reduce	  abdominal	  distension	  and	  
discomfort	  (Bausserman	  and	  Michail	  2005).	  
	  
IBD	  includes	  Crohn’s	  disease	  and	  ulcerative	  colitis.	  The	  aetiology	  is	  complex	  and	  not	  always	  
clear.	  It	   is	  suggested	  that	  IBD	  may	  be	  caused	  by	  a	  hyper-­‐responsive	  cell-­‐mediated	  immune	  
response	   to	   intestinal	   commensal	   bacteria	   or	   microbiota	   aberrancies	   in	   genetically	  
susceptible	   patients	   (Sartor	   2004,	   Iltanen	   et	   al.	   2006).	   The	   addition	   of	   specific	   probiotic	  
strains	   or	   their	   combination	   to	   the	   diet	   can	   eliminate	   the	   inflammation-­‐inducing	   bacteria	  
and	  may	  possibly	  treat	  active	  IBD.	  The	  beneficial	  effect	  of	  probiotics	  in	  the	  treatment	  of	  IBD	  
in	  children	  has	  been	  reported	  once;	  the	  specific	  probiotic	  preparation	  VSL#3	  combined	  with	  
standard	   therapy	   proved	   helpful	   in	   the	   treatment	   of	   chronic	   ulcerative	   colitis	   in	   children	  
(Miele	  et	  al.	  2009).	  
	  
A	   common	   condition	   typically	   affecting	   infants	   in	   the	   first	   4	   months	   of	   life	   is	   colic.	   The	  
aetiology	   is	   again	   complex	   and	   includes	   abnormal	   gastrointestinal	   function.	   The	  
administration	  of	  the	  probiotic	  L.	  reuteri	  ATCC	  55730	  has	  been	  shown	  to	  be	  effective	  in	  the	  
treatment	  of	  this	  condition	  (Savino	  et	  al.	  2007).	  
	  
Studies	  on	  the	  long-­‐term	  health	  benefits	  of	  probiotics	  for	  the	  development	  of	  the	  immune	  
system,	  prevention	  of	  cancer	  and	  treatment	  of	  allergy,	  diarrhoeas	  and	  NEC	  in	  children	  are	  
still	  ongoing	  and	  their	  effects	  need	  to	  be	  proved	  (Figure	  3).	  
Based	  on	   research	   reports	   and	   clinical	   intervention	   studies	   it	   has	   been	   concluded	   that	   all	  
probiotic	  health	  effects	  are	  strain-­‐,	  dose-­‐,	  disease-­‐	  and	  host-­‐dependent.	  
	  
	  
2.6	  Methods	  of	  microbiota	  analyses	  
	  
For	   an	   investigation	   of	   the	   intestinal	   microbiota,	   the	   easiest	   and	   most	   readily	   available	  
sample	  is	  the	  faeces.	  However,	  the	  faeces	  represent	  the	  intestinal	  microbiota	  in	  the	  lumen	  




of	   the	   sigmoid	   colon,	   while	   the	   microbial	   composition	   differs	   both	   along	   the	   GIT	   and	  
between	   the	   lumen	   and	   the	   mucosa	   (Probert	   and	   Gibson	   2002,	   Ouwehand	   et	   al.	   2004).	  
Samples	   taken	   at	   endoscopy	   or	   during	   surgery	   may	   however	   not	   well	   represent	   the	  
intestinal	  microbiota	  as	  the	  bowel	  cleansing	  and	  anaesthetics	  used	  during	  these	  procedures	  
may	   have	   an	   impact	   on	   the	   intestinal	   microbiota.	   It	   is	   of	   interest	   to	   study	   microbiota	  
associated	  with	   the	   intestinal	  mucosa	  as	  being	   in	   close	   contact	  with	   the	  human	   intestinal	  
tissue	  and	  thereby	  with	  the	  immune	  system	  of	  the	  host;	  the	  composition	  and	  activity	  of	  the	  
mucosal	  microbiota	  may	  be	  more	  relevant	  to	  host	  health	  than	  the	  luminal	  microbiota.	  
	  
Culture-­‐dependent	  methods	  
Culture-­‐dependent	   methods	   are	   based	   on	   isolation,	   identification	   and	   enumeration	   of	  
bacteria	  using	  classical	  microbiological	  methods.	  The	  counts	  of	  a	  specific	  bacterial	  group	  are	  
determined	   after	   incubation	   in	   appropriate	   conditions.	   These	   include	   media	   type	   (non-­‐
selective,	   selective),	   atmosphere	   (aerobic,	   anaerobic),	   temperature	   and	   other	   factors	  
influencing	   the	   growth	   of	   specific	   bacterial	   groups.	   Bacteria	   can	   be	   identified	   using	  
morphological	   examinations	   (colony	   and/or	   cell	   appearance),	   biochemical	   (biochemical	  
functional	  activities,	  gas	   liquid	  chromatography	  of	  bacterial	   fatty	  acids)	  and	  genetic	   (using	  
nucleic	  acid-­‐based	  methods)	   tests.	  However,	  morphological	  examinations	  and	  biochemical	  
tests	  lead	  to	  numerous	  misidentifications	  and	  should	  not	  be	  the	  sole	  approaches	  in	  bacterial	  
identification,	   even	   if	   helpful	   in	   assessing	   the	   phenotypic	   characteristics	   of	   the	   bacteria	  
studied.	  
Genetic	   techniques	   have	   contributed	   substantially	   to	   our	   knowledge	   of	   the	   intestinal	  
microbiota.	  Most	  genetic	  methods	  are	  based	  on	  the	  use	  of	  the	  ribosomal	  bacterial	  16S	  RNA	  
molecule	   (16S	   rRNA).	   Partial	   amplification	   and	   sequencing	   of	   the	   16S	   rRNA	   gene	   from	  
previously	   isolated	  colonies	  are	  used	   for	  detection	  and	  quantification	  of	  bacteria	  at	  genus	  
and	   species	   level.	   The	   use	   of	   16S	   rRNA	   techniques	   often	   however	   requires	   previous	  




Most	   of	   the	   bacteria	   inhabiting	   human	   gut	   have	   not	   yet	   been	   cultured	   in	   laboratory	  
conditions.	  Until	   now,	   researchers	   have	  been	   able	   to	   characterise	   about	   25%	  of	   the	   total	  




bacterial	  gut	  population	  using	  classical	  culture-­‐based	  methods.	  These	  methods	  are	  thus	  not	  
appropriate	  in	  describing	  the	  total	  microbial	  diversity.	  During	  the	  last	  few	  years,	  significant	  
progress	  in	  molecular	  biology	  has	  led	  to	  the	  development	  of	  culture-­‐independent	  methods	  
allowing	   identification	   and	   characterisation	   of	   numerous	   new	   bacterial	   groups.	   Culture-­‐
independent	   techniques	   are	  based	  mainly	  on	   the	  use	  of	   the	  16S	   rRNA	  molecule.	   The	  16S	  
rDNA	  gene	  is	  characterised	  by	  highly	  conserved	  and	  variable	  regions	  which	  are	  characteristic	  
for	  specific	  bacteria	  present	  in	  the	  gut.	  Based	  on	  these	  characteristics,	  specific	  primers	  and	  
probes	   can	   be	   designed	   to	   detect	   microbes	   sought.	   Techniques	   based	   on	   16S	   rRNA	   use	  
include	   polymerase	   chain	   reaction	   (PCR)	   and	   its	   variables,	   randomly	   amplified	  
polymorphism	  DNA	  (RAPD),	  temperature	  gradient	  gel	  electrophoresis	  /	  denaturing	  gradient	  
gel	   electrophoresis	   (TGGE/DGGE),	   terminal-­‐restriction	   fragment	   length	   polymorphism	   (T-­‐
RFLP),	   oligonucleotide	   arrays,	   fluorescent	   in	   situ	   hybridisation	   (FISH)	   (Tannock	   2001,	  
Albuquerque	  et	  al.	  2009,	  Turroni	  et	  al.	  2008).	  
	  
FISH	   and	   quantitative	   PCR	   (qPCR)	   are	   the	   methods	   established	   to	   determine	   the	   total	  
amounts	  and/or	  proportions	  of	  bacterial	  groups/species	  of	   interest	   in	  a	  complex	  microbial	  
community.	  
	  
The	   FISH	  method	   is	   commonly	   used	   in	  microbial	   ecological	   studies.	   The	   technique	   allows	  
visualisation	   of	   bacteria	   containing	   rRNA,	   which	   is	   targeted	   for	   hybridisation	   with	   a	  
fluorescently	  labeled	  oligonucleotides	  probe	  with	  a	  sequence	  specific	  for	  a	  bacterial	  species	  
or	   genus	   (directed	   toward	   the	   16S	   rRNA	   gene).	   The	   FISH	   method	   allows	   the	   analysis	   of	  
complex	  microbial	  communities	  such	  as	  the	  human	  faeces.	  A	  variety	  of	  microorganisms	  can	  
be	  quantitatively	  identified	  (Amann	  et	  al.	  1996,	  Albuquerque	  et	  al.	  2009).	  The	  combination	  
of	   FISH	  with	   flow	   cytometry	   (FCM-­‐FISH)	   detection	   appears	   to	   be	   a	   very	   high	   throughput	  
means	  to	  the	  identification	  and	  quantification	  of	  specific	  microorganisms.	  
	  
Quantitative	   PCR	   is	   widely	   used	   to	   detect	   and	   quantify	   specific	   DNA	   sequences	   of	  
microorganisms.	  The	  method	  is	  a	  particularly	  rapid	  and	  accurate	  means	  of	  determining	  the	  
amount	  of	  target	  DNA	  in	  a	  sample.	  Bacterial	  DNA	  can	  be	  isolated	  from	  the	  sample	  and	  the	  
rRNA	  genes	  can	  be	  amplified	  using	  the	  polymerase	  chain	  reaction	  (PCR).	  The	  choice	  of	  PCR	  
primers	  allows	  a	  wide	  spectrum	  of	  specificity.	   If	  general	  primers	  are	  used,	  almost	  all	  rRNA	  




sequences	   can	   be	   amplified.	   In	   contrast,	   if	   unique	   PCR	   primers	   are	   chosen,	   only	   a	   single	  
species	  or	  a	  small	  group	  of	  bacterial	  rRNA	  sequences	  in	  the	  sample	  will	  be	  amplified	  (Brunk	  
et	  al.	  2002,	  Albuquerque	  et	  al.	  2009).	  
	  
Novel	   techniques	   to	   study	   microbial	   communities	   focus	   on	   activity	   biomarkers	   such	   as	  































3.	  AIMS	  OF	  THE	  STUDY	  
	  
The	  main	  goal	  in	  the	  present	  series	  was	  to	  characterise	  the	  gut	  microbiota	  in	  early	  infancy	  
and	  the	  specific	  determinants	  influencing	  its	  composition.	  
	  
The	  specific	  aims	  were	  to	  assess:	  
	  
1.	  the	  association	  between	  the	  gut	  microbiota	  of	  mother	  and	  infant	  (I)	  
2.	   the	   effect	   of	   supplementation	   of	   probiotics	   in	   the	   last	   trimester	   of	   pregnancy	   on	   the	  
maternal	  and	  neonatal	  gut	  microbiota	  (I)	  
3.	  the	  gut	  microbiota	  in	  infants	  living	  in	  different	  human	  populations	  such	  as	  Malawian	  and	  
Finnish	  (II)	  
4.	  the	  gut	  microbiota	  in	  infants	  from	  Finland	  in	  comparison	  with	  infants	  in	  Germany	  (III)	  
5.	   the	  differences	   in	   the	   gut	  microbiota	   composition	  between	  breast-­‐fed	   and	   formula-­‐fed	  
infants	  from	  Germany	  (A)	  
6.	   the	   impact	   of	   probiotic	   administration	   to	   mother	   and/or	   infant	   on	   gut	   microbiota	   in	  
Finnish	  and	  German	  infants	  (III)	  























The	  profiles	  of	  each	  separate	  study	  (I,	  II,	  III,	  A)	  are	  presented	  in	  Figures	  4,	  5,	  6	  and	  7.	  
	  
	  
4.1.1	  Influence	  of	  mother’s	  intestinal	  microbiota	  on	  gut	  colonisation	  in	  the	  infant	  
	  
Figure	  4.	  Study	  I	  design	  
	  
To	   investigate	  mother-­‐infant	   association	   in	   the	   gut	   colonisation	   of	   1-­‐6-­‐month-­‐old	   infants	  
and	   to	   establish	   whether	   probiotics	   can	   influence	   this	   process,	   faecal	   samples	   from	   80	  
mother-­‐infant	  pairs	  were	  analysed	  at	  1	  month	  (mothers’	  postpartum	  time	  and	  infants’	  age)	  
and	  6	  months	  (infants’	  age)	  (I),	  (Figure	  4).	  The	  mother-­‐infant	  pairs	  were	  selected	  from	  the	  
main	  trial	  (Identifier:	  NCT00167700)	  on	  the	  criterion	  that	  the	  mother	  was	  exclusively	  breast-­‐
feeding	   the	   infant	   for	   a	   minimum	   of	   4	   months	   and	   partial	   /	   exclusive	   breast-­‐feeding	  
continued	  until	  the	  infant	  completed	  6	  months	  of	  age.	  This	  yielded	  80	  mother-­‐infant	  pairs.	  
The	  mothers	   received	  probiotic	   /	  placebo	   for	  2	  months	  before	  delivery,	  and	   for	  2	  months	  
At 1 month postpartum (mothers) 
At infant age 1 and 6 months 



















after	  delivery	  or	  until	  they	  stopped	  breast-­‐feeding.	  There	  were	  three	  intervention	  groups:	  1.	  
Lactobacillus	   rhamnosus	   LPR	   (CGMCC1.3724)	   with	   Bifidobacterium	   longum	   strain	   BL999	  
(ATCC:	   	   BAA-­‐999)	   (LPR+BL999,	   29	   mother-­‐infant	   pairs),	   2.	   Lactobacillus	   paracasei	   ST11	  
(CNCM	  1-­‐2116)	  with	  Bifidobacterium	   longum	  BL999	   (ST11+BL999,	   29	  mother-­‐infant	   pairs)	  
and	  3.	  Placebo	  (22	  mother-­‐infant	  pairs).	  The	  dose	  of	  probiotics	  was	  108	  /	  day	  of	  each	  strain	  
provided	  in	  one	  sachet	  of	  7	  g	  per	  day	  (powder	  form),	  diluted	  in	  a	  glass	  of	  water.	  Clinical	  data	  
on	  the	  study	  infants	  are	  shown	  in	  Table	  1.	  
Table	  1.	  Clinical	  characteristics	  of	  the	  infants	  in	  Study	  I.	  
	  
	   ST11+BL999	   LPR+BL999	   Placebo	   Total	  
	  Clinical	  characteristics	   (n=29)	   (n=29)	   (n=22)	   (n=80)	  
Vaginal	  delivery	   28	  (97%)	   28	  (97%)	   19	  (86%)	   75	  (94%)	  
Male	  sex	   14	  (48%)	   15	  (52%)	   9	  (41%)	   38	  (48%)	  
Gestational	  age	  (wk)	   41.0	  (36-­‐42)	   40.0	  (37-­‐42)	   39.5	  (35-­‐42)	   40.0	  (35-­‐42)	  
Weight	  at	  birth	  (g)	   3714	  (525)	   3614	  (523)	   3653	  (336)	   3661	  (476)	  
Height	  at	  birth	  (cm)	   51.7	  (2.4)	   50.5	  (2.1)	   50.8	  (1.6)	   51.0	  (2.1)	  
Apgar	  1	  minute	   9	  (2-­‐10)	   9	  (5-­‐10)	   9	  (3-­‐10)	   9	  (2-­‐10)	  
Apgar	  5	  minute	   9	  (3-­‐10)	   9	  (8-­‐10)	   9	  (6-­‐10)	   9	  (3-­‐10)	  
Apgar	  15	  minute	   9	  (4-­‐10)	   9	  (8-­‐10)	   9	  (8-­‐10)	   9	  (4-­‐10)	  
Antibiotics	  during	  labour	  or	  in	  delivery	  
hospital	   	   	   	   	  
Mother	   3	  (10%)	   4	  (14%)	   6	  (27%)	   13	  (16%)	  
Infant	   2	  (7%)	   3	  (10%)	   1	  (5%)	   6	  (8%)	  
Antibiotics	  <1	  month*	   1	  (3%)	   3	  (10%)	   1	  (5%)	   5	  (6%)	  
Antibiotics	  at	  1-­‐3	  months	   1	  (3%)	   0	   0	   1	  (1%)	  
Antibiotics	  at	  3-­‐6	  months	   5	  (17%)	   4	  (14%)	   4	  (18%)	   13	  (16%)	  
	  
Data	  are	  shown	  as	  number	  (%)	  and	  mean	  (SD)	  
*	  Given	  at	  home,	  not	  including	  those	  in	  hospital	  
	  
	  
4.1.2	  Gut	  microbiota	  profiles	   in	   infants	  residing	   in	  a	  South	  Eastern	  African	  and	  Northern	  
European	  country	  
	  
The	  aim	  of	  this	  study	  (II)	  was	  to	  compare	  the	  gut	  microbiota	  in	  6-­‐month-­‐old	  infants	  living	  in	  
rural	  Malawi	  with	   that	   in	  children	  of	   the	  same	  age	   living	   in	  urban	  Finland,	  both	  having	  an	  
age-­‐appropriate	  diet	  typical	  for	  each	  area	  (Figure	  5).	  	  
The	  Malawian	  study	  population	  comprised	  44	  healthy	  6-­‐month-­‐old	  rural	  infants,	  who	  were	  
enrolled	   for	   an	   epidemiological	   clinical	   trial	   assessing	   the	   impact	   of	   selected	   dietary	  




interventions	   on	   early	   childhood	   growth	   (Identifier:	   NCT00524446).	   The	  Malawian	   infants	  
represented	   a	   population	   typical	   of	   that	   age	   in	   Malawi.	   The	   clinical	   characteristics	   and	  
patterns	   of	   current	   dietary	   intakes	   of	   the	  Malawian	   infants	   participating	   in	   the	   study	   are	  













Figure	  5.	  Study	  II	  design	  
	  
Table	  2.	  Clinical	  characteristics	  the	  infants	  in	  Study	  II.	  
Clinical	  characteristics	   	  	  	  Malawian	  infants	  (n=44)	  	   Finnish	  infants	  (n=31)	  
Gender	   	   	  
Male	   20/44	  	  (45.5%)	   14/31	  (45.2%)	  
Female	   24/44	  	  (54.5%)	   18/31	  (54.8%)	  
Age	  (months)	   6.0	  (5.6-­‐6.0)	   6.1	  (5.9-­‐6.4)	  
Weight	  (kg)	   6.6	  (6.2-­‐7.2)	   8.1	  (7.5-­‐8.7)	  
Mode	  of	  delivery	  (%	  vaginal)	   Not	  known	   24/31	  (77.4%)	  
Breastfeeding	   44/44	  	  (100.0%)	   21/31	  (67.7%)	  
Breast	  milk	  +	  complementary	  food	   44/44	  	  (100.0%)	   18/31	  (58.1%)	  
Breast	  milk	  +	  complementary	  food	  +	  formula	   Non-­‐existent	   3/31	  (9.7%)	  
Formula	  +	  complementary	  food	   Non-­‐existent	   10/31	  (32.2%)	  
Breast	  milk	  +	  complementary	  food	  +	  other	  milk*	  	   18/44	  	  (40.9%)	   None	  
	  
Data	  on	  age	  and	  weight	  are	  shown	  as	  median	  with	  IQR.	  *Other	  milk	  includes	  cow’s	  and	  goat’s	  milk	  
	  
The	  Finnish	  study	  population	  comprised	  31	  healthy	  6-­‐month-­‐old	   infants	  participating	   in	  an	  
ongoing	  prospective	  randomised	  study	  in	  the	  city	  of	  Turku	  and	  neighboring	  areas	  in	  south-­‐
western	   Finland,	   (Identifier:	   NCT00167700,	   section	   3).	   The	   31	   infants	   represented	   a	  
population	   typical	   of	   that	   age	   group	   in	   Finland.	   The	   infants	   included	   in	   this	   study	  did	  not	  
At the age of 6 months 











receive	  probiotics	  or	  prebiotics	  and	  their	  mothers,	  if	  breast-­‐feeding,	  did	  not	  have	  probiotic	  
or	  prebiotic	  products	  in	  their	  diet.	  The	  mothers‘	  diets	  reflected	  the	  typical	  Finnish	  diet.	  The	  




4.1.3	   The	   impact	   of	   geographical	   location	   and	   diet	   on	   gut	   microbiota	   composition	   in	  
infants	  
	   	   	   	  
	   	   	   	  	  	  	  	  	  III	   	   	   	   	   	   	   A	  
	  
Figure	  6.	  Study	  III	  and	  A	  design	  
	  
To	  analyse	  the	   impact	  of	  the	  environment	  on	  gut	  microbiota	  composition,	  22	   infants	  from	  
Finland	  (placebo	  group	  from	  Study	   III)	  and	  8	  from	  Germany	  (additional	  group),	  both	  being	  
breast-­‐fed,	  were	  compared,	  (Figure	  6	  III).	  
In	  addition,	  8	  German	  breast-­‐fed	  infants	  (additional	  group)	  were	  compared	  with	  32	  German	  
formula-­‐fed	   infants	   (placebo	   group	   from	   Study	   III)	   in	   order	   to	   bring	   out	   differences	   in	  
microbiota	  composition,	  if	  any,	  (Figure	  6	  A).	  
Detailed	   information	  on	  22	   infants	   from	  Finland	   and	  32	   infants	   from	  Germany	   is	   given	   in	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4.1.4	  Perinatal	  probiotic	  intervention	  in	  6-­‐month-­‐old	  infants	  from	  two	  European	  locations	  
	  
To	  analyse	  the	  effect	  of	  probiotic	  administration	  to	  the	  mother	  or	  the	  infant,	  mothers	  and	  
their	   infants	   from	   Finland	   and	   infants	   from	   Germany	  were	   recruited	   (III),	   (Figure	   7).	   The	  
Finnish	   study	   cohort	   comprised	   79	   infants	   (Identifier:	   NCT00167700).	   The	   mothers	   in	  
Finland	  were	  chosen	  on	   the	  criterion	   that	   their	   infants	  were	  breast-­‐fed	  exclusively	  until	   4	  
months	  of	  age	  and	  partially	  /	  exclusively	  until	  6	  months.	  Probiotic	  product	  and	  placebo	  were	  
given	  to	   the	  mothers	   for	  2	  months	  before	  delivery	  and	   for	  2	  months	  after	  delivery	  during	  
breast-­‐feeding.	  Probiotics	  or	  placebo	  were	  used	  for	  a	  maximum	  of	  4	  months.	  Twenty-­‐eight	  
mothers	  received	  a	  probiotic	  product	  consisting	  of	  L.	  rhamnosus	  LPR	  (CGMCC	  1.3724)	  with	  
B.	   longum	   BL999	   (ATCC:	   BAA-­‐999),	   (LPR+BL999),	   29	   mothers	   received	   L.	   paracasei	   ST11	  
(CNCM	   1-­‐2116)	   with	   B.	   longum	   BL999	   (ST11+BL999),	   and	   22	   placebo.	   The	   dose	   to	   the	  
mother	  was	  108	  /	  day	  of	  each	  probiotic	  strain	  provided	  in	  one	  sachet	  of	  7	  g	  per	  day	  (powder	  
form),	  diluted	  in	  a	  glass	  of	  water.	  
	  




Finnish	  cohort	  	   	   	   	   	   German	  cohort	  
	  
Figure	  7.	  Study	  III	  design	  
	  
The	   German	   study	   population	   comprised	   81	   infants	   receiving	   formula	   with	   or	   without	  
probiotics.	  Twenty-­‐four	  infants	  received	  partially	  hydrolysed	  formula	  supplemented	  with	  L.	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At the age of 6 months 
Gut microbiota assessment by qPCR and FCM-FISH 




25	   received	   partially	   hydrolysed	   formula	   with	  B.	   longum	   BL999	   (ATCC:	   BAA-­‐999),	   and	   32	  
received	   partially	   hydrolysed	   formula.	   The	   probiotic	   and	   placebo	   formulas	   were	  
administered	  to	  the	  infants	  when	  they	  went	  onto	  formula,	  at	  the	  latest	  at	  1	  month	  of	  age.	  
The	  intervention	  lasted	  for	  4	  months.	  The	  dose	  of	  the	  probiotic	  was	  at	  least	  109	  CFU	  /	  day	  of	  













Figure	  8.	  Study	  IV	  design	  
	  
	  Table	  3.	  List	  of	  L.	  rhamnosus	  isolates	  and	  
source	  of	  isolation. 
















provided	  in	  soft	  agar	  
OL	   commercial	  food	  
Assessment of the impact of the manufacturing process 
Strain phenotypic and genotypic 
characterisation 
L. rhamnosus GG strain 
isolates 
Properties of adhesion and adhesion 
exclusion mechanisms with pathogens 
To	   investigate	   whether	   the	   properties	   of	   a	   specific	  
probiotic	  strain	  may	  differ	  depending	  on	  the	  product	  
and	  source	  of	  the	  strain	  (Figure	  8),	  13	  L.	  rhamnosus	  
isolates	   claimed	   to	   be	   L.	   rhamnosus	   GG	   (ATCC	  
53103)	   were	   isolated	   from	   different	   probiotic	  
products	   from	   different	   countries	   (Table	   3).	   For	  
comparison,	  the	  original	  L.	  rhamnosus	  GG	  (original	  L.	  
rhamnosus	   GG	   strain	   isolate	   donated	   by	   Professor	  
Sherwood	  Gorbach	  of	  Tufts	  University,	  Boston,	  MA,	  
USA)	   from	   which	   other	   cultures	   used	   in	   probiotic	  
products	  were	  derived	  was	  included	  (IV).	  




An	  additional	  commercial	  probiotic	  L.	  rhamnosus	  strain	  (identification	  code	  OL)	  of	  the	  same	  
species	  but	  known	  to	  be	  phenotypically	  different	  from	  L.	  rhamnosus	  GG	  was	  included	  as	  an	  
external	  reference	  strain (Figure	  8).	  	  
	  
For	   further	   assessment,	   the	   bacterial	   pathogens	   used	   were	   Cronobacter	   sakazakii	   (ATCC	  
29544),	   Staphylococcus	   aureus	   (DSM	   20231),	   Clostridium	   perfringens	   (DSM	   756)	   and	  





4.3.1	  Sample	  preparation	  and	  DNA	  extraction	  
	  
Faecal	   samples	  were	   taken	   for	   the	   analysis	   from	  mothers	   at	   1	  month	   postpartum	   (I)	   and	  
infants	  at	  1	  (I)	  and	  6	  months	  (II,	  III,	  A)	  of	  age	  and	  stored	  at	  -­‐80	  °C	  until	  analysis.	  	  
Faecal	   samples	   (0.5	  g)	  were	  weighed,	  diluted	  1:10	   (w/v)	   in	  phosphate	  buffer	  PBS	   (pH	  7.4)	  
and	  homogenised	  by	  thorough	  agitation	   in	  a	  vortex.	  Aliquots	  of	   these	  dilutions	  were	  used	  
for	   DNA	   extraction.	   DNA	   from	   both	   faeces	   and	   also,	   from	   pure	   cultures	   of	   the	   different	  
bacterial	   strains	   used	   as	   reference	   were	   extracted	   using	   the	   QIAamp	   DNA	   stool	  Mini	   kit	  
(Qiagen,	  Hilden,	  Germany)	  following	  the	  manufacturer’s	  instructions.	  
	  
	  
4.3.2	  Evaluation	  of	  prevalence	  of	  target	  species	  in	  faecal	  samples	  
	  
In	  detecting	   the	  presence	  of	   specific	  gut	  microbiota	   (I,	   II,	   III,	  A)	  qualitative	  PCR	  was	  used.	  
Amplification	  of	  the	  DNA	  was	  performed	  using	  a	  PCR	  iCycler	  (Bio-­‐Rad,	  Espoo,	  Finland).	  The	  
total	   volume	   of	   each	   PCR	   was	   50	   µL,	   including	   1	   µL	   of	   DNA	   extract	   as	   a	   template.	   The	  
reaction	  mixture	  was	   composed	  of	   1	   x	   PCR	  buffer	   II	   (Applied	  Biosystems,	   Foster	   City,	   CA,	  
USA),	  2.5	  mM	  MgCl2,	  0.2	  µM	  of	  each	  primer,	  200	  µL	  of	  each	  dNTP	  (Amersham	  Biosciences,	  
Helsinki,	   Finland)	   and	   1.25	   U	   AmpliTaq	   Gold	   DNA	   polymerase	   (Applied	   Biosystems).	   The	  
thermal	   cycle	   program	   consisted	   of	   the	   following	   time	   and	   temperature	   profile:	   an	   initial	  
cycle	  of	  95	  °C	  for	  10	  min	  for	  denaturation	  and	  polymerase	  activation,	  30	  cycles	  15	  s	  at	  95	  °C,	  




1	  min	  at	  the	  annealing	  temperature	  of	  the	  corresponding	  primer	  pair	  and	  45	  s	  at	  72	  °C	  and	  a	  
final	   extension	   step	   of	   10	   min	   at	   72	   °C.	   Amplified	   products	   were	   subjected	   to	   gel	  
electrophoresis	   in	  1%	  agarose	  gels	  and	  were	  visualised	  by	  ethidium	  bromide	  staining.	  The	  
following	   reference	   strains	  were	  used:	   Bifidobacterium	   genus,	  B.	   longum	   (DSM	  20219),	   B.	  
catenulatum	   (JCM	  7130),	  B.	  bifidum	   (DSM	  20456),	  B.	   lactis	   (DSM	  20606),	  B.	   infantis	   (DSM	  
20090),	  B.	  adolescentis	  (DSM	  20083),	  B.	  breve	  (DSM	  20213),	  Akkermansia	  muciniphila	  (ATTC	  
BAA-­‐835),	  S.	  aureus	  (DSM	  20231),	  C.	  coccoides	  (DSM	  935T),	  C.	  leptum	  (DSM	  753T),	  C.	  difficile	  
(DSM	  1296T)	  and	  C.	  perfringens	   (DSM	  756).	  The	  primer	  sequences	  of	  the	  reference	  strains	  
and	  the	  annealing	  temperatures	  of	  the	  primers	  have	  been	  published	  elsewhere	  (Matsuki	  et	  
al.	  1999,	  Penders	  et	  al.	  2006,	  Collado	  et	  al.	  2008).	  
	  
	  
4.3.3	  Real-­‐time	  polymerase	  chain	  reaction	  (qPCR)	  analysis	  of	  gut	  bacteria	  
	  
Quantitative	  real	  time	  PCR	  was	  used	  to	  characterise	  the	  faecal	  microbiota	  (I,	  II,	  III,	  A)	  using	  
group-­‐	   and	   species-­‐specific	   primers.	   These	   oligonucleotides	   were	   purchased	   from	   the	  
Thermo	  Electron	  Corporation	  (Thermo	  Biosciences,	  Ulm,	  Germany).	  
Briefly,	  PCR	  amplification	  and	  detection	  were	  performed	  with	  an	  ABI	  PRISM	  7300-­‐real-­‐time	  
PCR	  system	  (Applied	  Biosystems,	  Foster	  City,	  California).	  Each	  reaction	  mixture	  of	  25	  μl	  was	  
composed	  of	  Power	  SYBR	  Green	  PCR	  Master	  Mix	  (Applied	  Biosystems),	  1	  μl	  of	  each	  of	  the	  
specific	  primers	  at	  a	  concentration	  of	  0.2	  mol/L,	  and	  1	  μl	  of	  template	  DNA.	  The	  fluorescent	  
products	  were	  detected	   in	   the	   last	   step	  of	  each	  cycle.	  A	  melting	  curve	  analysis	  was	  made	  
after	  amplification	  to	  distinguish	  the	  targeted	  from	  the	  non-­‐targeted	  PCR	  product.	  	  
The	   bacterial	   concentration	   in	   each	   sample	   was	   calculated	   by	   comparing	   the	   Ct	   values	  
obtained	   from	   standard	   curves.	   A	   standard	   curve	  was	  made	   from	   serial	   dilutions	   of	   DNA	  
isolated	  from	  each	  pure	  culture	  of	  the	  different	  reference	  strains.	  A	  linear	  relationship	  was	  
observed	  between	  cell	  number	  and	  Ct	  values	  (r2	  =	  0.99-­‐0.97).	  	  
The	  following	  reference	  strains	  were	  used	  to	  construct	  the	  corresponding	  standard	  curves:	  
B.	   longum	   (DSM	   20219)	   (this	   strain	   was	   also	   used	   as	   the	   standard	   strain	   for	   the	  
quantification	   of	   Bifidobacterium	   genus),	   B.	   catenulatum	   (JCM	   7130),	   B.	   bifidum	   (DSM	  
20456),	   B.	   lactis	   (DSM	   20606),	   B.	   infantis	   (DSM	   20090),	   B.	   adolescentis	   (DSM	   20083),	   B.	  




breve	   (DSM	   20213),	   Akkermansia	  muciniphila	   (ATTC	   BAA-­‐835),	   S.	   aureus	   (DSM	   20231),	  C.	  
coccoides	   (DSM	   935T),	   C.	   leptum	   (DSM	   753T),	   C.	   difficile	   (DSM	   1296T)	   and	   C.	   perfringens	  
(DSM	  756).	  The	  primer	  sequences	  of	  the	  reference	  strains	  and	  the	  annealing	  temperatures	  
of	   the	   primers	   have	   been	   published	   elsewhere	   (Matsuki	   et	   al.	   1999,	   Penders	   et	   al.	   2006,	  
Collado	  et	  al.	  2008).	  
	  
	  
4.3.4	   Flow	   	   cytometry	   –	   fluorescent	   in	   situ	   hybridisation	   (FCM-­‐FISH)	   analysis	   of	   gut	  
bacteria	  
	  
Homogenised	   faecal	   samples	   (II,	   III,	  A)	  were	   fixed	  overnight	   in	   4%	  paraformaldehyde	  and	  
stored	  in	  PBS-­‐ethanol	  in	  -­‐20	  oC	  until	  analysed.	  Fluorescent	  in	  situ	  hybridisation	  coupled	  with	  
a	  flow	  cytometer	  was	  performed	  as	  previously	  described	  (Collado	  et	  al.	  2008,	  Kalliomäki	  et	  
al.	   2008).	   In	   brief,	   samples	   of	   the	   fixed	   cells	   were	   hybridised	   overnight	   at	   specific	  
temperatures	  in	  hybridisation	  buffer	  with	  specific	  probes	  at	  a	  concentration	  of	  5	  ng/µl.	  After	  
overnight	   hybridisation	   the	   samples	  were	  washed	  with	   buffer	  without	   SDS,	   pelleted,	   and	  
resuspended	   in	   PBS.	   The	   EUB338	   probes	   were	   covalently	   linked	   at	   their	   5´-­‐end	   with	  
fluorescein	   isothiocyanate	   (FITC)	   and	   other	   probes	   with	   carbocyanine	   3	   (Cy3)	   (Thermo	  
Biosciences,	   Ulm,	   Germany).	   Probes	   included:	   EUB338	   for	   the	   total	   bacteria,	   Bif164	   for	  
Bifidobacterium	   group,	   Bac303	   for	   Bacteroides-­‐Prevotella	   group,	   Chis150	   for	   Clostridium	  
histolyticum	  group,	  Lab158	  for	  Lactobacillus-­‐Enterococcus	  group,	  Muc1437	  for	  Akkermansia	  
muciniphila,	  with	   the	  probe	   sequences	  and	   references	  described	  elsewhere	   (Amann	  et	  al.	  
2001,	  Collado	  et	  al.	  2008,	  Franks	  et	  al.	  1998,	  Harmsen	  et	  al.	  1999,	  Langendijk	  et	  al.	  1995,	  
Manz	  et	  al.	  1996).	  Data	  acquisition	  was	  performed	  by	  LSR	  II	  flow	  cytometer	  equipped	  with	  a	  
HTS	   96-­‐well	   plate	   reader	   (Becton	   Dickinson,	   San	   Jose,	   USA).	   Forty	   µl	   of	   samples	   were	  
collected	   in	   duplicate	   of	   each.	   Data	   were	   analysed	  with	   BD	   FACSDiva™	   software	   (Becton	  
Dickinson).	  
The	  total	  amount	  of	  bacteria	  was	  determined	  with	  the	  EUB338-­‐FITC	  probe.	  Determination	  
of	  specific	  bacteria	  was	  performed	  by	  combining	  each	  of	  the	  group-­‐specific	  Cy3	  probes	  with	  
the	   EUB338-­‐FITC	   probe	   and	   counting	   double	   positive	   cells,	   as	   described	   elsewhere	  
(Rigottier-­‐Gois	  et	  al.	  2003).	  
	  




4.3.5	  Bacteria	  and	  growth	  conditions	  
	  
The	   L.	   rhamnosus	   isolates	   (IV)	   were	   grown	   in	   de	  Man,	   Rogosa	   and	   Sharpe	   broth	   (Oxoid	  
Limited,	   Basingstoke,	   Hampshire,	   UK)	   and	   incubated	   at	   37	   °C	   under	   anaerobic	   conditions	  




4.3.6	  Phenotypic	  and	  genotypic	  characterisation	  of	  bacteria	  
	  
Characterisation	  of	  the	  isolates	  by	  carbohydrate	  fermentation	  profiles	  
The	  fermentation	  ability	  of	  the	  L.	  rhamnosus	   isolates	  (IV)	  was	  obtained	  in	  API	  50	  CH	  strips	  
(Bio-­‐Mérieux,	  Marcy	  l’Etoile,	  France)	  following	  the	  manufacturer’s	  instructions.	  
	  
Tolerance	  to	  acid	  
Bacterial	  cultures	  (IV)	  (5	  ml)	  were	  grown	  overnight,	  cells	  were	  harvested,	  washed	  twice	  with	  
0.85%	   NaCl	   and	   resuspended	   in	   500	   µl	   of	   the	   same	   solution;	   100	   µl	   of	   the	   bacterial	  
suspensions	  (approximately	  108	  cells)	  were	  added	  to	  900	  µL	  of	  simulated	  gastric	  juice	  (125	  
mM-­‐NaCl,	  7	  mM-­‐KCl,	  45	  mM-­‐NaHCO3	  and	  pepsin	   (3	  g/l;	  Sigma))	  adjusted	  to	  pH	  2.0	  or	  2.5	  
with	  HCl.	   Suspensions	  were	   then	   incubated	   for	   90	  min.	   Plate	   counts	  were	  made	   at	   time-­‐
point	  0	  and	  after	  90	  min	  of	  incubation.	  
	  
Species	  identity	  of	  isolates	  by	  partial	  sequence	  analysis	  of	  the	  16S	  rRNA	  gene	  
The	  L.	  rhamnosus	  isolates	  used	  in	  the	  present	  study	  (IV)	  were	  identified	  at	  species	  level	  by	  
partial	   sequence	   analysis	   of	   the	   16S	   rRNA	   gene,	   followed	   by	   Blast	   analysis.	   In	   brief,	  
microorganisms	  were	  grown	  overnight,	  1	  ml	  of	  cells	  was	  harvested	  and	  the	  DNA	  extracted	  
using	   the	  GenElutee	  Bacterial	  Genomic	  DNA	  Kit	   (Sigma,	   St.	   Louis,	  MO,	  USA)	   following	   the	  
manufacturer’s	   instructions.	   Partial	   amplification	   of	   the	   16S	   rRNA	   gene	   and	   species	  
identification	  were	  carried	  out	  as	  previously	  described	  by	  Gueimonde	  and	  coworkers	  (2004).	  
Amplified	   PCR	  products	  were	   purified	   using	   the	  GenElutee	   PCR	  Clean-­‐Up	  Kit	   (Sigma),	   and	  
automated	  sequencing	  of	  the	  amplicons	  was	  carried	  out	  at	  Secugen	  SL	  (Madrid,	  Spain)	  in	  an	  
automated	   sequencer	   ABI	   Prism	   (Applied	   Biosystems).	   The	   sequences	   obtained	   were	  




compared	  with	  those	  held	  at	  the	  GenBank	  database	  using	  the	  Blast	  application	  at	  the	  NCBI	  
webpage.	  
	  
Randomly	  amplified	  polymorphic	  DNA-­‐PCR	  
DNA	  extracts	  from	  the	  different	  L.	  rhamnosus	   isolates	  (IV)	  were	  used	  for	  strain	  typification	  
by	  randomly	  amplified	  polymorphic	  DNA	  analysis	  using	  previously	  described	  conditions,	  the	  
primer	  for	  L.	  rhamnosus	  and	  methodology	  by	  Tynkkynen	  and	  collaborators	  (1999).	  
	  
Enterobacterial	  repetitive	  intergenic	  consensus-­‐PCR	  
Enterobacterial	  repetitive	  intergenic	  consensus-­‐PCR	  is	  based	  on	  the	  use	  of	  oligonucleotides	  
targeting	  short	  repetitive	  sequences	  distributed	  throughout	  the	  bacterial	  genome.	  Bacterial	  
DNA	   (IV)	   was	   amplified	   using	   primers	   5’-­‐ATGTAAGCTCCTGGGGATTCAC-­‐3’	   and	   5’-­‐
AAGTAAGTGACTGGGGTGAGCG-­‐3’	   (Sigma	  Genosys)	   as	   previously	   described	   (Ventura	   et	   al.	  
2003).	  
	  
DNA	  restriction	  patterns	  by	  pulsed-­‐field	  gel	  electrophoresis	  
The	   L.	   rhamnosus	   isolates	   (IV)	  were	   typified	   using	   analysis	   of	  DNA	   restriction	   patterns	   by	  
pulsed-­‐field	  gel	  electrophoresis	  (PFGE)	  as	  described	  elsewhere	  (Tynkkynen	  et	  al.	  1999).	  
	  
	  
4.3.7	  Adhesion	  assay	  with	  radiolabelled	  bacteria	  
	  
Mucus	  preparation	  
For	  the	  present	  study	  (IV)	  human	  intestinal	  mucus	  was	  obtained	  as	  described	  by	  Ouwehand	  
and	   coworkers	   (2002)	   from	   the	   healthy	   part	   of	   resected	   human	   colonic	   tissue	   and	   the	  
protein	   concentration	  was	   determined	   according	   to	   the	  method	   of	   Lowry	   and	   colleagues	  
(Lowry	   et	   al.	   1951,	   Miller	   and	   Hoskins	   1981).	   Human	   colonic	   mucus	   was	   dissolved	   (0.5	  
mg/ml	   protein)	   in	   HEPES	   (N-­‐2-­‐hydroxyethylpiperazine-­‐N-­‐2-­‐ethanosulphonic	   acid)–Hanks	  
buffer	   (HH;	   10	   mM	   HEPES,	   pH	   7.4),	   and	   100	   µL	   of	   this	   solution	   was	   immobilised	   in	  
polystyrene	   microtitre	   plate	   wells	   (Maxisorp,	   Nunc,	   Roskilde,	   Denmark)	   by	   overnight	  
incubation	  at	  4	  °C	  according	  to	  the	  method	  of	  Kirjavainen	  and	  colleagues	  (1998).	  
	  





For	  adhesion,	  inhibition,	  displacement	  and	  competition	  assays	  isolates	  (IV)	  were	  grown	  for	  
18	   h,	   harvested	   and	   then	   washed	   twice	   with	   phosphate-­‐buffered	   saline	   (PBS)	   buffer.	   All	  
microorganisms	  were	  metabolically	  labeled	  by	  addition	  to	  the	  media	  of	  10	  µL	  /	  mL	  tritiated	  
thymidine	  (5’-­‐3H-­‐thymidine	  1.0	  mCi	  /	  mL;	  Amersham	  Biosciences,	  Little	  Chalfont,	  Bucks,	  UK).	  
	  
Radiolabeled	   bacteria	  were	   centrifuged	   (6000	   rpm	   for	   7	  min)	   and	  washed	   twice	  with	  HH	  
buffer,	  and	  the	  absorbance	  (A600nm)	  was	  adjusted	  to	  0.25	  ±	  0.01	  to	  standardise	  the	  bacterial	  
concentration	   (108	   cells/ml).	   Thereafter,	   bacteria	   (100	   µL)	   were	   added	   to	   the	   wells	   and	  
incubated	  for	  1	  h	  at	  37	  °C.	  The	  wells	  were	  then	  washed	  twice	  with	  200	  µL	  of	  HH	  to	  remove	  
unbound	   bacteria.	   Adhering	   bacteria	   were	   released	   and	   lysed	   with	   1%	   (wt/vol)	   sodium	  
dodecyl	  sulfate	  (SDS)	  in	  0.1	  mol/litre	  NaOH	  (200	  µL	  per	  well)	  by	  incubation	  at	  60	  °C	  for	  1	  h.	  
The	  contents	  of	  the	  wells	  were	  transferred	  to	  microfuge	  tubes	  containing	  scintillation	  liquid	  
(OptiPhase	  ‘HiSafe	  3’,	  Wallac,	  Milton	  Keynes,	  UK),	  and	  the	  radioactivity	  measured	  by	  liquid	  
scintillation.	   Adhesion	   was	   expressed	   as	   the	   percentage	   of	   radioactivity	   recovered	   after	  
adhesion	  relative	  to	  the	  radioactivity	  of	  the	  bacterial	  suspension	  added	  to	  the	  immobilised	  
mucus.	  Adhesion	  was	  determined	   in	   three	   independent	  experiments,	   and	  each	  assay	  was	  
performed	  in	  triplicate	  to	  calculate	  intra-­‐assay	  variation.	  
	  
Exclusion	  assays	  
Exclusion	  by	   inhibition,	  displacement	  and	  competition	  assays	  was	  carried	  out	  as	  described	  
by	  Collado	  and	  coworkers	  (2007b,	  c).	  
The	  percentage	  of	  adhesion	  inhibition,	  displacement	  and	  competition	  was	  calculated	  as	  the	  
difference	   between	   the	   adhesion	   of	   the	   pathogen	   in	   the	   absence	   and	   presence	   of	   the	  
different	  isolates.	  Inhibition,	  displacement	  and	  competition	  assays	  were	  each	  conducted	  in	  
three	  independent	  experiments	  and	  each	  assay	  was	  performed	  in	  triplicate.	  
	  
	  
4.3.8	  Statistics	  	  
	  
Statistical	  analyses	  were	  performed	  using	  SPSS	  (SPSS	  Inc,	  Chicago,	  IL,	  USA)	  versions	  16.0	  (I),	  
17.0	  (III,A),	  18.0	  (IV)	  and	  SAS	  for	  Windows	  (version	  9.2,	  SAS	  Institute	  Inc.,	  Cary,	  NC,	  USA)	  (II).	  




For	   Studies	   I	   and	   III	   all	   subjects	  were	   chosen	  and	   identified	  by	  a	   statistician	  using	   criteria	  
provided.	  The	  randomisation	  codes	  (I,	  III)	  were	  available	  to	  the	  statistician	  alone	  in	  order	  to	  
maintain	  blindness	  for	  the	  ongoing	  main	  studies.	  	  
	  
Study	  I:	  The	  Mantel-­‐Haenszel	  method	  was	  applied	  to	  estimate	  the	  odds	  ratio	  (OR)	  for	  each	  
study	   group	   and	   to	   obtain	   a	   combined	  OR	   estimate	  with	   a	   95%	   confidence	   interval.	   The	  
Breslow-­‐Day	  test	  was	  used	  to	  analyse	  homogeneity	  between	  odds	  ratios,	  i.e.	  the	  interaction	  
between	  probiotic	   intervention	  and	  maternal	  colonisation.	  The	  non-­‐parametric	  correlation	  
was	  used	  to	  verify	  the	  results,	  when	  appropriate.	  Analysis	  of	  covariance	  (ANCOVA)	  was	  used	  
to	   detect	   the	   possible	   interaction	   between	   probiotic	   intervention	   and	   maternal	   faecal	  
counts,	   i.e.	   to	   test	  whether	   the	   relation	  between	  maternal	  and	   infants’	   faecal	   counts	  was	  
affected	  by	   the	  probiotic	   intervention.	  A	  bifidobacterial	  diversity	   index	   (DI)	  was	  calculated	  
for	   the	  mothers	  at	  1	  month	  after	  delivery	  and	   for	   the	   infant	  at	  1	  and	  6	  months	  of	  age	  as	  
follows:	  DI=(A/B)x100,	  where	  A	  represents	  the	  number	  of	  bifidobacteria	  species	  found	  in	  a	  
sample	  and	  B	  the	  total	  number	  of	  bifidobacteria	  species	  analysed	  (=7)	  (Shadid	  et	  al.	  2007).	  A	  
bifidobacterial	   similarity	   index	   (SI)	   in	   the	   mother-­‐infant	   pairs	   was	   calculated	   at	   1	   and	   6	  
months	   after	   delivery	   correspondingly:	   SI=(C/D)x100,	   where	   C	   represents	   the	   number	   of	  
bifidobacteria	   species	   found	   in	   both	   the	  mother	   and	   the	   infant	   and	   D	   the	   number	   of	   all	  
bifidobacteria	  species	  found	  in	  the	  mother,	  the	  infant	  or	  both	  (Shadid	  et	  al.	  2007).	  Kruskal-­‐
Wallis	   1-­‐way	   ANOVA	   and	   Mann-­‐Whitney	   U-­‐test	   were	   used	   to	   compare	   these	   indices	  
between	  study	  groups	  and	  between	  categories	  of	  other	  explaining	  factors,	  and	  the	  Wilcoxon	  
signed-­‐rank	  test	  was	  used	  to	  test	  changes	  from	  1	  month	  to	  6	  months.	  The	  DI	  and	  SI	  were	  
further	   analysed	   using	   different	   ordinal	   regression	   models,	   where	   colonisation,	   use	   of	  
antibiotics,	   mode	   of	   delivery,	   probiotic	   intervention	   and	   mother’s	   DI	   were	   included	   as	  
explaining	  factors.	  Spearman	  rank	  correlation	  was	  used	  to	  study	  the	  association	  between	  DI	  
and	  SI	  indices	  in	  mothers	  and	  infants.	  
	  
Study	  II:	  Continuous	  variables	  were	  compared	  between	  Malawian	  and	  Finnish	  children	  using	  
the	   Kruskall-­‐Wallis	   test.	   Continuous	   variables	   are	   presented	   using	   medians	   with	   inter-­‐
quartile	   ranges	   (IQR).	  Fisher’s	  exact	   test	  was	  used	  to	  establish	  the	  percentages	  of	  positive	  
values	  for	  qPCR.	  
	  




Study	  III,	  A:	  The	  bacterial	  counts	  and	  percentages	  detected	  by	  qPCR	  and	  FCM-­‐FISH	  analysis	  
were	  the	  primary	  variables.	  The	  counts	  were	  not	  normally	  distributed	  and	  are	  expressed	  as	  
medians	  with	  inter-­‐quartile	  ranges	  (IQR)	  and	  analysed	  using	  non-­‐parametric	  methods.	  In	  the	  
FCM-­‐FISH	  results	  the	  bacterial	  counts	  as	  percentages	  of	  total	  bacterial	  counts	  were	  normally	  
distributed,	   and	  were	   thus	   expressed	   as	  means	  with	   95%	   confidence	   interval	   (95%	  CI).	   In	  
qPCR	  results	  the	  Chi-­‐squared	  test	  was	  used	  to	  compare	  the	  percentages	  of	  infants	  positive	  
for	  the	  specified	  bacteria	  and	  the	  Kruskal-­‐Wallis	  test	  to	  compare	  counts	  of	  bacteria	  in	  those	  
cases	  where	  at	  least	  50%	  of	  the	  infants	  were	  positive	  in	  all	  study	  groups.	  Analysis	  of	  variance	  
(ANOVA)	   was	   used	   to	   analyse	   differences	   between	   intervention	   groups.	   All	   post-­‐hoc	  
comparisons	  were	  Bonferroni-­‐corrected.	  
	  
Study	  IV:	  The	  adhesion	  (%)	  measured	  in	  different	  conditions	  was	  here	  the	  primary	  endpoint.	  
One-­‐way	   ANOVA	  was	   used	   to	   test	   the	   overall	   difference	   in	   adhesion	   properties	   between	  
strains.	  When	  p<0.10,	  Dunnett’s	   (two-­‐tailed)	   t	   test	  was	  used	   to	   compare	  each	   strain	  with	  
the	  reference	  strain	  L.	  rhamnosus	  GG	  without	  any	  other	  pairwise	  comparisons.	  The	  cut-­‐off	  
point	  to	  indicate	  statistical	  significance	  was	  not	  strictly	  set	  at	  0.05	  due	  to	  the	  small	  sample	  
size	  and	  large	  type	  II	  error.	  Based	  on	  Dunnett’s	  t	  test,	  the	  exact	  P	  values	  are	  given,	  where	  
both	   0.05	   and	   0.10	   were	   used	   as	   cut-­‐off	   points	   to	   indicate	   the	   degree	   of	   statistical	  





The	   studies	   were	   approved	   by	   the	   Committee	   on	   Ethical	   Practice	   of	   Turku	   University	  
Hospital	   in	   Finland	   (I,	   II,	   III),	   the	   ethical	   Committee	   of	   the	   Pirkanmaa	   Hospital	   District	   in	  
Finland	  (II),	  the	  College	  of	  Medicine	  Research	  and	  Ethics	  Committee	  of	  University	  of	  Malawi	  
in	  Malawi	  (II)	  and	  the	  Marien-­‐Hospital	  Wesel	  in	  Germany	  (III,	  A).	  Infants	  and	  mothers	  were	  











5.1	  Intestinal	  microbial	  association	  between	  mother	  and	  infant	  during	  prenatal	  period	  
	  
Association	  of	  bacterial	  colonisation	  rates	  between	  mothers	  and	  infants	  
	  
The	  overall	  colonisation	  rates	  in	  mothers	  and	  infants	  with	  the	  different	  bacteria	  studied	  (I)	  
are	  shown	  in	  Table	  4.	  
Probiotic	   intervention	  had	  no	  effect	  on	  the	  colonisation	  rates	  or	   faecal	  bacterial	  counts	   in	  
mothers	  (data	  not	  shown).	  
When	  all	  mother-­‐infant	  pairs	  were	  analysed	  together,	  it	  emerged	  that	  the	  colonisation	  rate	  
of	   B.	   bifidum	   was	   significantly	   associated	   in	   the	   mother-­‐infant	   pairs	   at	   1	   month	   and	   6	  
months	   after	   delivery	   (Table	   5).	   Thus,	   if	   the	   mother	   was	   positive	   for	   B.	   bifidum	   the	  
likelihood	  of	  the	  child	  being	  positive	  was	  19	  times	  higher	  (95%	  CI	  5.18-­‐69.69,	  p<0.001)	  at	  1	  
month	  and	  23	  times	  higher	  (95%	  CI	  5.36-­‐100.0,	  p<0.001)	  at	  6	  months	  of	  age	  compared	  to	  
infants	  whose	  mothers	  were	  negative	  for	  B.	  bifidum.	  Likewise	  colonisation	  by	  B.	  breve	  was	  
significantly	   associated	   between	  mothers	   and	   infants	   at	   1	  month	   after	   delivery	   (OR	   6.89,	  
95%	  CI	  1.62-­‐29.29,	  p=0.009),	  but	  not	  at	  6	  months.	  	  
	  
Table	   4.	   Colonisation	   rates	   of	   faecal	  microbiota	   in	  mothers	   1	  month	   postpartum	   and	   in	   infants	   at	   1	   and	   6	  
months	  of	  age.	  
	   Prevalence	  of	  positive	  samples	  (%)	  
Bacteria	   Mother	   	   Infant,	  1	  month	   	   Infant,	  6	  months	  
	  	   (n=76)	   	  	   (n=80)	   	  	   (n=79)	  
Bifidobacterium	  genus	   100	   	   96.3	   	   100	  
B.longum	   98.7	   	   88.8	   	   94.9	  
B.catenulatum	   61.8	   	   31.3	   	   51.9	  
B.lactis	   60.5	   	   17.5	   	   38.0	  
B.adolescentis	   57.9	   	   6.3	   	   13.9	  
B.bifidum	   38.2	   	   42.5	   	   51.9	  
B.infantis	   11.8	   	   6.3	   	   29.1	  
B.breve	   14.5	   	   28.8	   	   64.6	  
C.coccoides	  	   100	   	   25.3	   	   83.3	  
C.leptum	   100	   	   25.0	   	   68.4	  
C.perfringens	   8.0	   	   11.3	   	   12.7	  
C.difficile	   2.7	   	   0	   	   21.5	  
A.muciniphila	   85.3	   	   2.5	   	   12.7	  






The	  colonisation	  rates	  of	  S.	  aureus	  tended	  to	  be	  associated	  between	  mothers	  and	  infants	  at	  
1	  month	  after	  delivery;	  if	  the	  mother	  was	  colonised	  with	  S.	  aureus	  the	  likelihood	  of	  the	  child	  
being	  colonised	  was	  3.23	  times	  higher	  (95%	  CI	  0.93-­‐11.18,	  p=0.064)	  than	  if	  the	  mother	  was	  
not	  colonised.	  At	  6	  months	  no	  such	  association	  was	  observed.	  
	  
No	  other	  significant	  or	  marginally	  significant	  associations	  were	  detected	  between	  mothers	  
and	  infants	  in	  the	  colonisation	  rates	  of	  other	  bacteria	  (data	  not	  shown).	  	  
	  
There	  was	  no	  evidence	  that	  probiotic	  intervention	  could	  modulate	  the	  level	  of	  association	  in	  
faecal	   bacterial	   colonisation	   rates	   between	   mothers	   and	   infants	   either	   during	   probiotic	  
supplementation	   (1	   month	   after	   delivery)	   or	   thereafter	   (6	   months	   after	   delivery).	  
Substantial	  differences	  in	  odds	  ratios	  were	  observed	  between	  the	  study	  groups,	  but	  due	  to	  
the	  small	  sample	  size,	  the	  interactions	  were	  not	  significant	  (Breslow-­‐Day	  test,	  Table	  5).	  	  
	  
Correlation	  of	  bacterial	  counts	  between	  mothers	  and	  infants	  
	  
When	  all	  mother-­‐infant	  pairs	  were	  assessed	   together	   (I),	   a	  positive	   correlation	  was	   found	  
between	   maternal	   and	   infant	   faecal	   counts	   of	   the	   genus	   Bifidobacterium	   during	  
supplementation	   (1	   month	   after	   delivery)	   (R=0.31,	   p=0.006)	   as	   well	   as	   a	   trend	   towards	  
correlation	  after	  supplementation	  (6	  months	  after	  delivery)	  (R=	  0.20,	  p=0.089).	  The	  counts	  
of	   B.	   longum	   did	   not	   correlate	   between	   mothers	   and	   infants	   at	   1	   month	   after	   delivery	  
(R=0.14,	  p=0.22),	  while	  a	  significant	  positive	  correlation	  was	  detected	  at	  6	  months	  (R=0.24,	  
p=0.038).	  
	  
Interactions	   were	   tested	   in	   quantitative	   analysis	   to	   establish	   whether	   the	   correlations	  
between	   faecal	   bacterial	   counts	   of	   mothers	   and	   infants	   were	   affected	   by	   the	   probiotic	  
intervention	   (I).	   The	   interactions	   were	   non-­‐significant	   during	   supplementation	   (1	   month	  
after	   delivery)	   (p=0.11	   for	   the	   Bifdobacterium	   genus	   and	   p=0.40	   for	   B.	   longum)	   but	  
significant	   after	   conclusion	   of	   supplementation	   (6	   months	   after	   delivery)	   (p=0.043	   for	  









































































































































































































































































































































































































































































































































In	  sub-­‐group	  analysis	  at	  6	  months	  after	  delivery	  the	  only	  positive	  correlation	  in	  faecal	  counts	  
of	  Bifidobacterium	  between	  mothers	  and	   infants	  was	   found	   in	   the	  placebo	  group	  (R=0.48,	  
p=0.028),	  whereas	  in	  the	  faecal	  counts	  of	  B.	  longum	  a	  positive	  correlation	  between	  mothers	  
and	  infants	  was	  found	  in	  the	  placebo	  (R=0.50,	  p=0.022)	  and	  the	  ST11+BL999	  groups	  (R=0.41,	  
p=0.032).	  
	  
Bifidobacterial	  diversity	  indices	  and	  mother-­‐infant	  similarity	  indices	  
	  
The	  median	  (IQR)	  bifidobacterial	  diversity	  index	  (DI)	  was	  50%	  (28.6%-­‐57.1%)	  in	  the	  mothers	  
at	  1	  month	  after	  delivery	  and	  28.6%	  (14.3%-­‐42.9%)	  and	  42.9%	  (28.6%-­‐71.4%)	  in	  the	  infants	  
at	   1	   and	   6	   months	   of	   age,	   respectively,	   without	   any	   significant	   differences	   between	   the	  
intervention	   groups	   (I).	   In	   infants,	   the	   change	   in	   DI	   from	   1	   to	   6	   months	   was	   significant	  
(p<0.001).	  The	  bifidobacterial	  DI	  correlated	  significantly	  between	  mothers	  and	   infants	  at	  1	  
month	   (rho=0.358,	   p=0.001).	   Also,	   infants’	   DI	   at	   1	   and	   6	   months	   of	   age	   correlated	  
(rho=0.356,	  p=0.001).	  	  
	  
It	   was	   further	   explored	   whether	   maternal	   intestinal	   colonisation	   with	   some	   specific	  
bifidobacteria	  species	  could	  be	  associated	  with	  the	  bifidobacterial	  DI	  of	  the	  infants	  at	  1	  and	  
6	   months	   of	   age.	   Comparisons	   between	   infants	   of	   colonised	   and	   non-­‐colonised	  mothers	  
showed	   that	   detection	  of	  B.	   bifidum	   in	   the	  mothers’	   intestinal	  microbiota	  was	   associated	  
with	  significantly	  higher	  faecal	  bifidobacterial	  DI	  in	  the	  infants	  both	  at	  1	  and	  6	  months	  of	  age	  
(p<0.001	  and	  p=0.03,	   respectively,	  Table	  6).	  Also,	  mothers’	  colonisation	  with	  B.	  breve	  was	  
associated	  with	  higher	  bifidobacterial	  DI	   in	   infants	  at	  1	  and	  6	  months	  of	  age	  (p=0.004	  and	  
p=0.072,	  respectively,	  Table	  6).	  	  
In	   addition,	   the	   effect	   of	   other	   background	   factors	   (mode	   of	   delivery,	   use	   of	   antibiotics,	  
mother’s	   DI,	   probiotic	   intervention),	   together	   with	   mother’s	   bifidobacterial	   colonisation	  
status,	  on	   the	   infants’	  bifidobactrial	  DI	  at	  1	  and	  6	  months	  of	  age	  was	  analysed	  by	  ordinal	  
regression	   analysis,	   but	   no	   single	   factor	   other	   than	   maternal	   B.	   bifidum	   and	   B.	   breve	  























































































































































































































































































































































































The	   similarity	   index	   (SI)	   between	   infants’	   and	   mothers’	   bifidobacterial	   microbiota	   was	  
analysed	  at	  1	  and	  6	  months	  after	  delivery	  (I).	  Median	  (IQR)	  SI	  between	  mothers	  and	  infants	  
was	   40%	   (25.5%-­‐50.0%)	   at	   1	   month	   and	   40%	   (28.6%-­‐50.0%)	   at	   6	   months	   after	   delivery,	  
without	   significant	   differences	   between	   intervention	   groups	   or	   between	   1	   and	   6	  months.	  
Detection	  of	  B.	  bifidum	  in	  the	  mother’s	  faecal	  microbiota	  was	  associated	  with	  higher	  SI	  at	  1	  
and	  6	  months	  after	  delivery	  (p=0.028	  and	  p=0.031,	  respectively,	  Table	  7).	  Further,	  detection	  
of	   B.	   lactis	   in	   the	  mothers’	   faecal	   microbiota	   was	   associated	   with	   infants’	   higher	   SI	   at	   6	  
months	  after	  delivery	  (p=0.033,	  Table	  7).	  	  
According	   to	   univariate	   and	   multivariate	   analysis,	   other	   background	   factors	   (mode	   of	  
delivery,	  use	  of	  antibiotics,	  mother’s	  DI,	  probiotic	  intervention)	  had	  no	  effect	  on	  the	  infant	  
SI	  at	  1	  or	  6	  months	  of	  age	  (data	  not	  shown).	  
	  
	  
5.2.	  Effect	  of	  environmental	  factors	  in	  shaping	  the	  gut	  microbiota	  in	  infants	  
	  
In	  Study	   II,	  differences	   in	   the	  gut	  microbiota	  composition	  of	  Malawian	  and	  Finnish	   infants	  
were	   observed	   in	   most	   bacteria	   assessed.	   Percentages	   of	   Bifidobacterium	   group,	  
Bacteroides-­‐Prevotella	   group,	   Clostridium	   histolyticum	   group	   and	   the	   total	   number	   of	  
bacteria	  detected	  by	  FCM-­‐FISH	  were	  significantly	  higher	  in	  Malawian	  than	  in	  Finnish	  infants	  
(70.8%	  vs.	  46.8%,	  p<0.001;	  17.2%	  vs.	  4.7%,	  p<0.001;	  4.4%	  vs.	  2.8%,	  p=0.01;	  90.9%	  vs.	  58.6%,	  
p<0.001;	  respectively),	  (Figure	  9).	  
	  
Likewise	   the	   counts	   of	   Bifidobacterium,	   Bacteroides-­‐Prevotella,	   Clostridium	   histolyticum	  
groups	  and	  the	  total	  number	  of	  bacteria	  detected	  by	  FCM-­‐FISH	  were	  significantly	  higher	  in	  
the	  Malawian	  infants	  (9.2	  log	  cells/g,	  IQR	  8.4-­‐9.6	  vs.	  8.4	  log	  cells/g	  IQR	  8.0-­‐8.7,	  p<0.001;	  8.6	  
log	  cells/g,	  IQR	  8.1-­‐8.9	  vs.	  7.5	  log	  cells/g	  IQR	  6.9-­‐8.0,	  p<0.001;	  8.0	  log	  cells/g,	  IQR	  7.6-­‐8.4	  vs.	  
7.3	  log	  cells/g,	  IQR	  6.2-­‐7.6,	  p<0.001;	  9.4	  log	  cells/g,	  IQR	  8.8-­‐9.8	  vs.	  8.8	  log	  cells/g	  IQR	  8.4-­‐9.0,	  
p=0.003,	  respectively).	  	  
	  
At	  the	  same	  time,	  using	  qPCR	  higher	  counts	  of	  the	  Bifidobacterium	  genus	  and	  the	  species	  B.	  
longum	  and	  B.	  bifidum	  were	  detected	  in	  higher	  amounts	  in	  Malawian	  compared	  to	  Finnish	  





The	   B.	   catenulatum,	   A.	   muciniphila	   and	   C.	   difficile	   species	   were	   rare	   in	   Malawian	   as	  
compared	   to	   Finnish	   infants.	   Bacteria	   belonging	   to	   the	   B.	   adolescentis,	   S.	   aureus	   and	   C.	  
perfringens	  species,	  present	  in	  Finnish,	  were	  not	  detectable	  in	  Malawian	  infants	  (Table	  8).	  
	  
	  
Figure	   9.	   Percentages	   of	   the	  major	   bacterial	   groups	   as	   compared	   to	   the	   total	   amount	   of	   bacteria	   in	   faecal	  
samples	   from	   6-­‐month-­‐old	   breast-­‐fed	  Malawian	   and	   Finnish	   infants	   in	   Study	   II,	   analysed	   by	   FCM-­‐FISH.	   The	  
white	  bars	  indicate	  Malawian	  and	  grey	  bars	  Finnish	  subjects.	  The	  line	  in	  the	  box	  represents	  the	  median	  (50th	  
percentile),	   the	   lower	   line	   the	   25%	   border	   (25th	   percentile)	   and	   the	   upper	   line	   the	   75%	   border	   (75th	  
percentile).	   The	  end	  of	   the	  upper	   vertical	   line	   represents	   the	  maximum	  data	  value,	  outliers	  not	   considered.	  















































Table	   8.	   Bacterial	   prevalences	   and	   counts	   (log	   cells/g)	   in	   faecal	   samples	   from	   6-­‐month-­‐old	   Malawian	   and	  
Finnish	  infants	  in	  Study	  II,	  analysed	  by	  qPCR.	  
	  
	   Malawian	  infants	  (n=44)	   	  	  	  	  	  	  	  Finnish	  infants	  (n=31)	   Comparison	  of	  groups	  
Bacteria	   %	   Median	  (IQR)	   %	   Median	  (IQR)	   P1	   P2	  
Bifidobacterium	  genus	  	   100.0	   10.4	  (10.0-­‐11.2)	   100.0	   10.0	  (9.4-­‐10.4)	   ND	   0.04	  
B.longum	  	   100.0	   10.3	  (9.8-­‐10.8)	   100.0	   9.1	  (7.3-­‐9.8)	   ND	   <0.001	  
B.catenulatum	   47.7	   0	  (0-­‐7.5)	   83.8	   5.8	  (4.9-­‐9.5)	   0.017	   0.056	  
B.bifidum	  	   97.8	   10.1	  (9.0-­‐10.8)	   58.1	   5.9	  (0-­‐9.2)	   1.666E-­‐04	   <0.001	  
B.adolescentis	  	   0	   0	   32.3	   0	  (0-­‐4.8)	   5.351E-­‐04	   <0.001	  
B.breve	  	   93.2	   7.8	  (6.9-­‐8.7)	   83.9	   7.2	  (6.7-­‐10.1)	   2.629	   9.356	  
C.coccoides	  	   65.9	   6.0	  (0-­‐7.4)	   100.0	   9.08	  (8.2-­‐9.6)	   1.917E-­‐03	   <0.001	  
C.leptum	   40.9	   0	  (0-­‐6.4)	   87.1	   6.7	  (5.8-­‐7.7)	   9.083E-­‐04	   <0.001	  
C.difficile	  	   9.1	   0	   45.2	   0	  (0-­‐8.9)	   6.545E-­‐03	   0.004	  
C.perfringens	   0	   0	   19.4	   0	   0.037	   0.025	  
A.muciniphila	  	   2.3	   0	   38.7	   0	  (0-­‐3.9)	   5.068E-­‐04	   <0.001	  
S.aureus	  	   0	   0	   54.8	   5.4	  (0-­‐7.1)	   8.937E-­‐08	   <0.001	  
	  
P1	  –	  Fisher’s	  exact	   test	  was	  used	  to	  test	   the	  percentages	  of	  positive	  values;	  P2	  –	  The	  Kruskal-­‐Wallis	   test	  was	  
used	  to	  test	  counts	  of	  bacteria;	  ND,	  not	  defined	  
	  
	  
5.3	  Gut	  microbiota	  in	  relation	  to	  geographical	  location	  and	  diet	  
	  
In	   Study	   III,	   the	   percentage	   of	   the	   Bifidobacterium	   group	   among	   the	   total	   number	   of	  
bacteria	  detected	  by	  FCM-­‐FISH	  tended	  to	  be	  higher	  in	  Finnish	  than	  in	  German	  infants	  (68.1%	  
vs.	   58.3%,	   p=0.142).	   Similarly,	   qPCR	   identified	   a	   trend	   towards	   higher	   counts	   of	  
bifidobacteria	   in	  Finnish	   infants	  (10.68	   log	  cells/g,	   IQR	  10.20-­‐11.35	  vs.	  9.90	   log	  cells/g,	   IQR	  
9.40-­‐10.78,	   p=0.097).	   A	   significantly	   higher	   percentage	   of	   the	   total	   bacterial	   count	  
comprised	  Akkermansia	  muciniphila	   in	  German	   as	   compared	   to	   Finnish	   breast-­‐fed	   infants	  
(8.6%	  vs.	  4.7%,	  p=0.004,	  Table	  9)	  and	  the	  Akkermansia	  muciniphila	  counts	  were	  also	  higher	  
(7.81	  log	  cells/g,	  95%	  CI	  7.49-­‐8.14	  vs.	  7.21	  log	  cells/g,	  95%	  CI	  6.99-­‐7.43,	  p=0.003;).	  Likewise	  
Clostridium	  histolyticum	   and	  Bacteroides-­‐Prevotella	  group	   counts	  were	   significantly	  higher	  
in	   German	   compared	   to	   Finnish	   infants	   (7.67	   log	   cells/g,	   95%	   CI	   7.16-­‐8.17	   vs.	   7.26	   log	  
cells/g,	  95%	  CI	  7.08-­‐7.44,	  p=0.035;	  7.84	  log	  cells/g	  95%	  CI	  7.47-­‐8.21	  vs.	  7.42	  log	  cells/g	  95%	  








Table	   9.	   Percentages	   of	   the	  major	   bacterial	   groups	   as	   compared	   to	   the	   total	   amount	   of	   bacteria	   in	   faecal	  
samples	  from	  6-­‐month-­‐old	  breast-­‐fed	  Finnish	  and	  German	  infants	  analysed	  by	  FCM-­‐FISH.	  
	  
	   Finnish	  infants	  (n=22)	   	   German	  infants	  (n=8)	   	  
%	  Bacteria	   Mean	   95%	  CI	   	   Mean	   95%	  CI	   P#	  
Bifidobacterium	   68.1	   57.0-­‐79.3	   	   58.3	   39.5-­‐77.0	   0.142	  
Bacteroides-­‐Prevotella	   7.4	   6.0-­‐8.9	   	   8.7	   5.0-­‐12.4	   0.504	  
Clostridium	  histolyticum	   5.3	   4.5-­‐6.1	   	   5.6	   4.2-­‐7.0	   0.447	  
Lactobacillus-­‐Enterococcus	   6.1	   5.2-­‐7.0	   	   6.7	   4.9-­‐8.5	   0.597	  
Akkermansia	  muciniphila	   4.7	   4.3-­‐5.1	   	   8.6	   3.7-­‐13.4	   0.004	  
Total	   91.7	   79.9-­‐103.4	   	   87.8	   68.8-­‐106.9	   0.447	  
	  
#	  Mann-­‐Whitney	  U	  test	  
	  
When	  the	  gut	  microbiota	  was	  compared	  between	  breast-­‐fed	  and	  formula-­‐fed	  infants	  from	  
Germany	   (A),	   it	   was	   noted	   that	   the	   percentage	   of	   the	  Bifidobacterium	   group	   among	   the	  
total	  number	  of	  bacteria	  detected	  by	  FCM-­‐FISH	   tended	   to	  be	  higher	   in	  breast-­‐fed	   than	   in	  
formula-­‐fed	  infants	  (58.3%	  vs.	  43.4%,	  p=0.06),	  (Table	  10).	  Using	  qPCR,	  the	  Bifidobacterium	  
group	  was	  found	  to	  be	  dominant,	  with	  a	  100%	  colonisation	  rate	  and	  the	  highest	  counts	   in	  
both	  cohorts	  studied.	  
	  
Table	   10.	   Percentages	   of	   the	  major	   bacterial	   groups	   as	   compared	   to	   the	   total	   amount	   of	   bacteria	   in	   faecal	  
samples	  from	  6-­‐month-­‐old	  breast-­‐fed	  and	  formula-­‐fed	  German	  infants	  analysed	  by	  FCM-­‐FISH.	  
	  
	   Breast-­‐fed	  infants	  (n=8)	   	   Formula-­‐fed	  infants	  (n=32)	   	  
%	  Bacteria	   Mean	   95%	  CI	   	   Mean	   95%	  CI	   P#	  
Bifidobacterium	   58.3	   39.5-­‐77.0	   	   43.4	   36.62-­‐50.10	   0.060	  
Bacteroides-­‐Prevotella	   8.7	   5.0-­‐12.4	   	   10.7	   7.92-­‐13.42	   0.489	  
Clostridium	  histolyticum	   5.6	   4.2-­‐7.0	   	   6.0	   5.01-­‐6.96	   0.695	  
Lactobacillus-­‐Enterococcus	   6.7	   4.9-­‐8.5	   	   6.0	   5.37-­‐6.56	   0.294	  
Akkermansia	  muciniphila	   8.6	   3.7-­‐13.4	   	   6.5	   5.39-­‐7.56	   0.178	  
Total	   87.8	   68.8-­‐106.9	   	   72.5	   64.1-­‐80.9	   0.105	  
	  
#	  Mann-­‐Whitney	  U	  test	  
	  
Significantly	   lower	   counts	   of	   B.	   catenulatum,	   C.	   coccoides,	   C.	   leptum,	   C.	   difficile,	   A.	  
muciniphila	  and	   S.	   aureus	  were	   found	   in	   breast-­‐fed	   than	   in	   formula-­‐fed	   infants	   (p=0.045,	  
p=0.001,	  p=0.005,	  p=0.016,	  p=0.003,	  p=0.045,	  respectively).	  Further,	  the	  colonisation	  rates	  
of	  B.	  catenulatum	  C.	  coccoides,	  C.	   leptum,	  A.	  muciniphila	  and	  S.	  aureus	   (p=0.038,	  p=0.004,	  
p=0.004,	   p=0.001,	   p=0.038,	   respectively)	   were	   lower	   in	   breast-­‐fed	   when	   compared	   to	  






Table	   11.	  Bacterial	   prevalences	   and	   counts	   (log	   cells/g)	   in	   faecal	   samples	   from	   6-­‐month-­‐old	   breast-­‐fed	   and	  
formula-­‐fed	  German	  infants,	  analysed	  by	  qPCR.	  
	  
	   Breast-­‐fed	  infants	  (n=8)	   	  	  	  	  	  	  	  	  Formula-­‐fed	  infants	  (n=32)	   Comparison	  of	  groups	  
	   %	   Median	  (IQR)	   	   %	   Median	  (IQR)	   P1	   	   P2	   	  
Bifidobacterium	  genus	  	   100.0	   9.90	  (9.40-­‐10.78)	   	   100.0	   10.31	  (9.94-­‐11.01)	   ND	   0.182	  
B.longum	  	   87.5	   10.02	  (8.86-­‐11.05)	   	   96.9	   10.17	  (7.69-­‐10.91)	   0.277	   0.906	  
B.catenulatum	   0	   5.14	  (5.14-­‐5.14)	   	   37.5	   5.14	  (5.14-­‐7.71)	   0.038	   0.045	  
B.bifidum	  	   50.0	   2.72	  (0-­‐8.59)	   	   78.1	   8.71	  (5.69-­‐9.85)	   0.111	   0.081	  
B.lactis	  	   75.0	   6.08	  (1.27-­‐6.23)	   	   59.4	   7.36	  (2.88-­‐9.57)	   0.414	   0.266	  
B.infantis	   25.0	   6.46	  (6.46-­‐7.61)	   	   25.0	   6.46	  (6.46-­‐6.46)	   1.000	   0.756	  
B.adolescentis	  	   0	   5.00	  (5.00-­‐5.00)	   	   34.4	   5.00	  (5.00-­‐6.75)	   0.051	   0.059	  
B.breve	  	   87.5	   8.44	  (6.19-­‐8.65)	   	   53.1	   5.70	  (4.38-­‐8.22)	   0.076	   0.090	  
C.coccoides	  	   75.0	   9.59	  (2.36-­‐9.87)	   	   100.0	   10.86	  (10.49-­‐11.40)	   0.004	   0.001	  
C.leptum	  	   75.0	   5.51	  (1.08-­‐6.43)	   	   100.0	   6.96	  (6.11-­‐7.95)	   0.004	   0.005	  
C.difficile	  	   25.0	   5.15	  (5.15-­‐5.09)	   	   62.5	   8.18	  (5.15-­‐9.45)	   0.057	   0.016	  
C.perfringens	   0	   6.43	  (6.43-­‐6.43)	   	   15.6	   6.43	  (6.43-­‐6.43)	   0.232	   0.239	  
A.muciniphila	  	   0	   1.88	  (1.88-­‐1.88)	   	   65.6	   4.04	  (1.88-­‐5.26)	   0.001	   0.003	  
S.aureus	  	   0	   4.87	  (4.87-­‐4.87)	   	   37.5	   4.87	  (4.87-­‐5.08)	   0.038	   0.045	  
	  
P1	  –	  Chi-­‐squared	  test	  was	  used	  to	  test	  the	  percentages	  of	  positive	  values;	  P2	  –	  Kruskal-­‐Wallis	  test	  was	  used	  to	  
test	  the	  counts	  for	  bacteria	  having	  ≥	  50%	  positive	  values	  in	  all	  study	  groups;	  ND,	  not	  defined	  
	  
	  
5.4	  Impact	  of	  specific	  probiotic	  administration	  on	  the	  gut	  microbiota	  composition	  
	  
In	  Study	  III,	  in	  Finnish	  infants	  who	  received	  probiotics	  bifidobacteria	  were	  the	  most	  common	  
bacteria,	   this	   group’s	   means	   being	   between	   63.8%	   and	   69.5%	   of	   the	   total	   bacteria.	   The	  
percentages	  of	  Bacteroides-­‐Prevotella,	  Clostridium	  histolyticum,	   Lactobacillus-­‐Enterococcus	  
groups	  and	  Akkermansia	  muciniphila	  were	  relatively	  small	  among	  the	  gut	  microbiota	  of	  all	  
groups	   studied.	   The	   percentages	   of	   the	  major	   bacterial	   groups	   as	   compared	   to	   the	   total	  
bacteria	  in	  infants	  assessed	  by	  FCM-­‐FISH	  are	  presented	  in	  Table	  12.	  	  
	  
Using	  qPCR,	  the	  Bifidobacterium	  group	  was	  found	  to	  be	  the	  dominant	  bacteria,	  with	  a	  100%	  
colonisation	   rate	  and	   the	  highest	   counts.	  Among	  bifidobacteria,	  B.	   longum	   numbers	  were	  
the	  highest.	  In	  all	  study	  groups	  qPCR	  identified	  high	  levels	  of	  C.	  coccoides.	  The	  colonisation	  








Table	   12.	   Percentages	   of	   the	  major	   bacterial	   groups	   as	   compared	   to	   the	   total	   amount	   of	   bacteria	   in	   faecal	  
samples	   from	   6-­‐month-­‐old	   Finnish	   infants	   from	   Study	   III,	   whose	   mothers	   were	   treated	   with	   probiotics	  
(ST11+BL999	  or	  LPR+BL999)	  or	  placebo	  2	  months	  prior	  to	  and	  2	  months	  after	  delivery.	  
	  
Faecal	  microbiota	  analysed	  by	  FCM-­‐FISH;	  ST11+BL999	  (L.	  paracasei	  ST11	  and	  B.	  longum	  BL999);	  LPR+BL999	  (L.	  
rhamnosus	   LPR	   and	   B.	   longum	   BL999);	   the	   figures	   in	   the	   table	   represent	   the	   percentages	   of	   the	   named	  
bacterial	  group	  as	  against	  total	  count	  detected	  by	  FCM-­‐FISH;	  1ANOVA	  was	  used	  to	  detect	  the	  overall	  difference	  
between	  the	  study	  groups;	  2Bonferroni-­‐adjusted	  post	  hoc	  comparisons:	  ST11+BL999	  vs.	  LPR+BL999,	  p=0.105;	  
ST11+BL999	  vs.	  placebo,	  p=0.438;	  LPR+BL999	  vs.	  placebo,	  p=0.003	  
	  
There	  was	  a	  significant	  difference	  in	  the	  percentage	  of	  the	  Lactobacillus-­‐Enterococcus	  group	  
(p=0.003):	   in	   STT11+BL999	   this	   group	   comprised	  7.3%	  of	   the	   total	   bacteria,	   in	   LPR+BL999	  
9.0%	   and	   in	   the	   placebo	   group	   6.1%	   (Table	   12).	   Post-­‐hoc	   comparisons	   revealed	   that	   the	  
difference	  between	  the	  LPR+BL999	  vs.	  placebo	  group	  was	  statistically	  significant	  (p=0.003).	  
In	  addition,	  there	  was	  a	  trend	  towards	  divergent	  percentages	  of	  the	  Bacteroides-­‐Prevotella	  
group	  between	  the	  intervention	  groups	  (p=0.097),	  with	  a	  significant	  difference	  in	  post-­‐hoc	  
comparison	   between	   LPR+BL999	   vs.	   placebo	   group	   (11.8%	   vs.	   7.4%,	   p=0.003).	   Also,	  
Bifidobacterium	   counts	  at	  genus	   level	  were	  significantly	  different	  among	   the	  study	  groups	  
(p=0.017);	  the	  counts	  were	  lower	  in	  the	  LPR+BL999	  group	  when	  compared	  to	  placebo	  (10.03	  
log	   cells/g	   vs.	   10.68	   log	   cells/g,	   p=0.018),	   which	   later	   had	   the	   highest	   counts	   among	   the	  
intervention	  groups	  (Table	  13).	  
	  
Further,	   the	   colonisation	   rates	   of	   B.	   longum	   and	   B.	   infantis	   differed	   between	   the	   study	  
groups	   (p=0.026	   and	   p=0.039,	   respectively).	   The	   B.	   longum	   rate	   was	   lower	   in	   the	  
ST11+BL999	  group	  (86.2%)	  when	  compared	  to	  the	  other	  two	  groups	  (both	  100%).	  B.	  infantis	  





	   ST11+BL999	  (n	  =	  29)	   	   LPR+BL999	  (n	  =	  28)	   	   	  	  Placebo	  (n	  =	  22)	   	   	  
%	  Bacteria	   Mean	  	   95%	  CI	   	  	   	  Mean	  	   95%	  CI	   	  	   Mean	  	   95%	  CI	   	  	   P1	  
Bifidobacterium	   63.8	   54.6-­‐72.9	   	   69.5	   61.0-­‐77.9	   	   68.1	   57.0-­‐79.3	   	   0.642	  
Bacteroides-­‐Prevotella	   9.9	   7.1-­‐12.7	   	   11.8	   8.5-­‐15.0	   	   7.4	   6.0-­‐8.9	   	   0.097	  
Clostridium	  histolyticum	   6.6	   4.9-­‐8.2	   	   6.0	   5.2-­‐6.9	   	   5.3	   4.5-­‐6.1	   	   0.361	  
Lactobacillus-­‐Enterococcus	   7.3	   6.4-­‐8.3	   	   9.0	   7.5-­‐10.4	   	   6.1	   5.2-­‐7.0	   	   0.0032	  
Akkermansia	  muciniphila	   5.2	   4.7-­‐5.8	   	   5.4	   4.8-­‐6.1	   	   4.7	   4.3-­‐5.1	   	   0.163	  





Table	   13.	   Bacterial	   prevalences	   and	   counts	   (log	   cells/g)	   in	   faecal	   samples	   from	   6-­‐month-­‐old	   Finnish	   infants	  
from	  Study	  III,	  whose	  mothers	  were	  treated	  with	  probiotics	  (ST11+BL999	  or	  LPR+BL999)	  or	  placebo,	  2	  months	  
prior	  to	  and	  2	  months	  after	  delivery.	  	  
	  
	   STT11+BL999	  (n=29)	   LPR+BL999	  (n=28)	   Placebo	  (n=22)	   Comparison	  of	  groups	  
	   %	   Median	  (IQR)	   %	   Median	  (IQR)	   %	   Median	  (IQR)	   P1	   P2	  
Bifidobacterium	  genus	  	   100.0	   10.61	  (9.80-­‐11.04)	   100.0	   10.03	  (9.52-­‐10.57)	   100.0	   10.68	  (10.20-­‐11.35)	   -­‐	   0.017	  
B.longum	  	   86.2	   9.87	  (7.40-­‐10.48)	   100.0	   9.67	  (8.44-­‐10.12)	   100.0	   10.02	  (8.92-­‐10.79)	   0.026	   0.325	  
B.catenulatum	   65.5	   5.79	  (5.14-­‐8.54)	   42.9	   5.14	  (5.14-­‐7.44)	   45.5	   5.14	  (5.14-­‐5.85)	   0.179	   ND	  
B.bifidum	  	   51.7	   5.44	  (5.00-­‐7.93)	   53.6	   6.66	  (5.00-­‐8.76)	   50.0	   5.69	  (5.00-­‐9.60)	   0.969	   0.605	  
B.lactis	  	   37.9	   2.88	  (2.88-­‐6.35)	   28.6	   2.88	  (2.88-­‐4.68)	   50.0	   4.10	  (2.88-­‐6.63)	   0.301	   ND	  
B.infantis	   44.8	   6.46	  (6.46-­‐7.73)	   14.3	   6.46	  (6.46-­‐6.46)	   27.3	   6.46	  (6.46-­‐6.48)	   0.039	   ND	  
B.adolescentis	  	   17.2	   5.00	  (5.00-­‐5.00)	   14.3	   5.00	  (5.00-­‐5.00)	   9.1	   5.00	  (5.00-­‐5.00)	   0.705	   ND	  
B.breve	  	   69.0	   7.19	  (4.38-­‐9.42)	   57.1	   5.34	  (4.38-­‐7.39)	   68.2	   8.63	  (4.38-­‐9.80)	   0.593	   0.101	  
C.coccoides	  	   79.3	   9.08	  (6.28-­‐10.51)	   85.2	   8.92	  (6.19-­‐9.76)	   86.4	   9.00	  (7.29-­‐10.30)	   0.760	   0.580	  
C.leptum	   72.4	   5.64	  (3.50-­‐6.33)	   78.6	   5.76	  (3.74-­‐6.52)	   50.0	   3.63	  (3.50-­‐6.13)	   0.082	   0.175	  
C.difficile	  	   27.6	   5.15	  (5.15-­‐6.18)	   14.3	   5.15	  (5.15-­‐5.15)	   22.7	   5.15	  (5.15-­‐5.62)	   0.468	   ND	  
C.perfringens	   13.8	   6.43	  (6.43-­‐6.43)	   11.1	   6.43	  (6.43-­‐6.43)	   13.6	   6.43	  (6.43-­‐6.43)	   0.947	   ND	  
A.muciniphila	  	   20.7	   1.88	  (1.88-­‐1.88)	   3.6	   1.88	  (1.88-­‐1.88)	   13.6	   1.88	  (1.88-­‐1.88)	   0.149	   ND	  
S.aureus	  	   34.5	   4.87	  (4.87-­‐5.31)	   28.6	   4.87	  (4.87-­‐4.89)	   36.4	   4.87	  (4.87-­‐5.46)	   0.823	   ND	  
	  
Faecal	   microbiota	   analysed	   by	   qPCR;	   ST11+BL999	   (L.	   paracasei	   ST11	   and	   B.	   longum	   BL999),	   LPR+BL999	   (L.	  
rhamnosus	   LPR	  and	  B.	   longum	  BL999).	  %,	  percentage	  of	  positive	  values;	   IQR,	   interquartile	   range	  (25th,	  75th	  
percentiles);	  P1	  –	  Chi-­‐squared	  test	  was	  used	  to	  test	  the	  percentages	  of	  positive	  values;	  P2	  –	  Kruskal-­‐Wallis	  test	  
was	  used	  to	  test	  the	  counts	  for	  bacteria	  having	  ≥	  50%	  positive	  values	  in	  all	  study	  groups;	  Bonferroni-­‐adjusted	  
post	   hoc	   comparisons	   for:	  B.	   genus	   (counts):	   ST11+BL999	   vs.	   LPR+BL999,	   p=0.143;	   ST11+BL999	   vs.	   placebo,	  
p=1.000;	  LPR+BL999	  vs.	  placebo,	  p=0.018.	  B.	  longum	  (%):	  ST11+BL999	  vs.	  LPR+BL999,	  p=0.125;	  ST11+BL999	  vs.	  
placebo,	   p=0.209.	   B.	   infantis	   (%):	   ST11+BL999	   vs.	   LPR+BL999,	   p=0.035;	   ST11+BL999	   vs.	   placebo,	   p=0.597;	  
LPR+BL999	  vs.	  placebo,	  p=0.763;	  ND,	  not	  defined	  
	  
In	   Study	   III,	   in	   German	   infants	   who	   received	   probiotics,	   bifidobacteria	   were	   the	   most	  
common	  bacteria,	  with	   intervention	   group	  means	   between	   43.4%	   and	   46.6%	  of	   the	   total	  
bacteria.	  The	  proportions	  of	  the	  major	  bacterial	  groups	  as	  compared	  to	  the	  total	  amount	  of	  
bacteria	  were	  not	  influenced	  by	  probiotic	  treatments	  (Table	  14).	  
	  
Using	  qPCR,	  bifidobacteria	  and	  clostridia	  were	  the	  most	  frequently	  detected	  bacteria	  and	  B.	  
longum	  and	  C.	  coccoides	  reached	  the	  highest	  counts	  in	  all	  intervention	  groups	  (Table	  15).	  
Probiotic	  treatment	  had	  an	  impact	  on	  the	  colonisation	  rate	  (p=0.029)	  and	  levels	  (p=0.044)	  of	  
B.	   bifidum	   (Table	   15);	   the	   lowest	   colonisation	   rate	   of	  B.	   bifidum	   was	   in	   the	   BL999	   group	  
(44.0%)	   compared	   to	   other	   groups	   (LPR+BB999	   58.3%,	   placebo	   78.1%),	   while	   post-­‐hoc	  
comparisons	  showed	  that	   infants	   receiving	   formula	  with	  LPR+BL999	  tended	  to	  have	   lower	  






Table	   14.	   Percentages	   of	   the	  major	   bacterial	   groups	   as	   compared	   to	   the	   total	   amount	   of	   bacteria	   in	   faecal	  
samples	   from	   6-­‐month-­‐old	   German	   infants	   from	   Study	   III,	   treated	  with	   probiotics	   (BL999	   or	   LPR+BL999)	   or	  
placebo	  at	  weaning	  at	  the	  latest	  at	  1	  month	  of	  age	  and	  continued	  for	  4	  months.	  
	  
	   BL999	  (n	  =	  25)	   	   LPR+BL999	  (n	  =	  24)	   	   Placebo	  (n	  =	  32)	   	   	  
%	  Bacteria	   Mean	  	   95%	  CI	   	  	  Mean	  	   95%	  CI	   	  	   Mean	  	   95%	  CI	   	  	   P1	  
Bifidobacterium	   44.2	   33.18-­‐55.30	   	   46.6	   37.14-­‐56.09	   	   43.4	   36.62-­‐50.10	   	   0.863	  
Bacteroides-­‐Prevotella	   10.1	   7.08-­‐13.16	   	   10.2	   6.64-­‐13.73	   	   10.7	   7.92-­‐13.42	   	   0.958	  
Clostridium	  histolyticum	   6.0	   4.78-­‐7.24	   	   6.1	   4.26-­‐7.87	   	   6.0	   5.01-­‐6.96	   	   0.996	  
Lactobacillus-­‐Enterococcus	   6.0	   4.91-­‐7.02	   	   5.8	   4.38-­‐7.27	   	   6.0	   5.37-­‐6.56	   	   0.975	  
Akkermansia	  muciniphila	   7.0	   4.51-­‐9.40	   	   6.3	   3.70-­‐8.96	   	   6.5	   5.39-­‐7.56	   	   0.907	  
Total	   73.3	   61.3-­‐85.3	   	   75.0	   63.5-­‐86.5	   	   72.5	   64.1-­‐80.9	   	   0.939	  
	  
Faecal	   microbiota	   analysed	   by	   FCM-­‐FISH;	   BL999	   (B.	   longum	   BL999);	   LPR+BL999	   (L.	   rhamnosus	   LPR	   and	   B.	  
longum	   BL999);	   the	   figures	   in	   the	   table	   represent	   the	   percentages	   of	   the	  named	  bacterial	   group	   as	   against	  




Table	  15.	   Bacterial	   prevalences	  and	   counts	   (log	   cells/g)	   in	   faecal	   samples	   from	  6-­‐month-­‐old	  German	   infants	  
from	  Study	  III,	  treated	  with	  probiotics	  (BL999	  or	  LPR+BL999)	  or	  placebo	  at	  weaning	  at	  the	  latest	  at	  1	  month	  of	  
age	  and	  continued	  for	  4	  months.	  	  
	  
	   BL999	  (n=25)	   LPR+BL999	  (n=24)	   Placebo	  (n=32)	   Comparison	  of	  groups	  
	   %	   Median	  (IQR)	   %	   Median	  (IQR)	   %	   Median	  (IQR)	   P1	   P2	  
Bifidobacterium	  genus	  	   100.0	   10.57	  (9.73-­‐10.99)	   100.0	   10.25	  (9.99-­‐10.50)	   100.0	   10.31	  (9.94-­‐11.01)	   ND	   0.719	  
B.longum	  	   100.0	   10.59	  (9.60-­‐11.19)	   100.0	   10.34	  (9.75-­‐10.80)	   96.9	   10.17	  (7.69-­‐10.91)	   0.461	   0.452	  
B.catenulatum	   44.0	   5.14	  (5.14-­‐6.23)	   37.5	   5.14	  (5.14-­‐7.66)	   37.5	   5.14	  (5.14-­‐7.71)	   0.858	   ND	  
B.bifidum	  	   44.0	   5.00	  (5.00-­‐9.34)	   58.3	   5.76	  (5.00-­‐8.83)	   78.1	   8.71	  (5.69-­‐9.85)	   0.029	   0.044	  
B.lactis	  	   64.0	   6.62	  (2.88-­‐7.46)	   62.5	   6.32	  (2.88-­‐9.46)	   59.4	   7.36	  (2.88-­‐9.57)	   0.934	   0.461	  
B.infantis	   24.0	   6.46	  (6.46-­‐6.56)	   25.0	   6.46	  (6.46-­‐7.21)	   25.0	   6.46	  (6.46-­‐6.46)	   0.995	   ND	  
B.adolescentis	  	   20.0	   5.00	  (5.00-­‐5.00)	   29.2	   5.00	  (5.00-­‐6.79)	   34.4	   5.00	  (5.00-­‐6.75)	   0.488	   ND	  
B.breve	  	   72.0	   7.45	  (4.38-­‐8.78)	   58.3	   7.06	  (4.38-­‐8.61)	   53.1	   5.70	  (4.38-­‐8.22)	   0.340	   0.349	  
C.coccoides	  	   96.0	   10.94	  (10.35-­‐11.34)	   95.8	   10.64	  (9.94-­‐11.28)	   100.0	   10.86	  (10.49-­‐11.40)	   0.512	   0.563	  
C.leptum	  	   96.0	   7.29	  (6.87-­‐8.03)	   95.8	   7.40	  (6.69-­‐8.00)	   100.0	   6.96	  (6.11-­‐7.95)	   0.512	   0.745	  
C.difficile	  	   56.0	   7.85	  (5.15-­‐9.14)	   58.3	   7.80	  (5.15-­‐8.98)	   62.5	   8.18	  (5.15-­‐9.45)	   0.879	   0.451	  
C.perfringens	   8.0	   6.43	  (6.43-­‐6.43)	   12.5	   6.43	  (6.43-­‐6.43)	   15.6	   6.43	  (6.43-­‐6.43)	   0.686	   ND	  
A.muciniphila	  	   48.0	   1.88	  (1.88-­‐5.82)	   50.0	   2.84	  (1.88-­‐5.63)	   65.6	   4.04	  (1.88-­‐5.26)	   0.334	   ND	  
S.aureus	  	   56.0	   4.87	  (4.87-­‐5.37)	   41.7	   4.87	  (4.87-­‐5.13)	   37.5	   4.87	  (4.87-­‐5.08)	   0.358	   ND	  
	  
Faecal	  microbiota	  analysed	  by	  qPCR;	  BL999	   (B.	   longum	  BL999);	  LPR+BL999	   (L.	  rhamnosus	  LPR	  and	  B.	   longum	  
BL999).	  %,	  percentage	  of	  positive	  values;	   IQR,	   	   interquartile	   range	   (25th,	  75th	  percentiles);	  P1	  –	  Chi-­‐squared	  
test	  was	  used	  to	  test	  the	  percentages	  of	  positive	  values;	  P2	  –	  Kruskal-­‐Wallis	  test	  was	  used	  to	  test	  the	  counts	  for	  
bacteria	   having	   ≥	   50%	  positive	   values	   in	   all	   study	   groups.	   Bonferroni-­‐adjusted	   post-­‐hoc	   comparisons	   for:	  B.	  
bifidum	   (%):	  BL999	  vs.	   LPR+BL999,	  p=0.947;	  BL999	  vs.	  placebo,	  p=0.024;	  LPR+BL999	  vs.	  placebo,	  p=0.333.	  B.	  
bifidum	  (counts):	  BL999	  vs.	  LPR+BL999,	  p=1.000;	  BL999	  vs.	  placebo,	  p=0.156;	  LPR+BL999	  vs.	  placebo,	  p=0.078;	  








5.5	  In	  vitro	  evaluation	  of	  commercially	  used	  probiotic	  L.	  rhamnosus	  GG	  
	  
Identification	  at	  species	  level	  and	  genotypic	  and	  phenotypic	  characterisation	  of	  the	  isolates	  
	  
In	  Study	  IV	  all	  the	  L.	  rhamnosus	  isolates	  used	  were	  confirmed	  as	  members	  of	  the	  species	  in	  
question	  by	  partial	  sequencing	  of	  the	  16S	  rDNA.	  Sequence	  analysis	  showed	  100%	  sequence	  
homology	  among	  the	  different	  L.	   rhamnosus	   isolates	  studied	  as	  well	  as	  with	  L.	   rhamnosus	  
16S	  rDNA	  sequences	  held	  in	  the	  databases	  (data	  not	  shown).	  
	  
All	   the	  L.	  rhamnosus	   isolates	  except	  the	  reference	  strain	  OL	  showed	  RAPD,	  ERIC	  and	  PFGE	  
profiles	   identical	   to	   that	  of	   the	  original	  L.	   rhamnosus	  GG	   isolate	  obtained	   from	  Professors	  
Gorbach	   and	   Goldin.	   These	   three	   techniques	   allowed	   differentiation	   of	   the	   isolate	   L.	  
rhamnosus	  OL	  from	  the	  other	  L.	  rhamnosus	  isolates.	  
	  
With	   regard	   to	  phenotypic	   characterisation,	   none	  of	   the	  L.	   rhamnosus	   isolates	   fermented	  
glycerol,	   erythiol,	   L-­‐arabinose,	   D-­‐xylose,	   L-­‐xylose,	   D-­‐adonitol,	   methyl-­‐βD-­‐xylopyranoside,	  
inositol,	   methyl-­‐αD-­‐mannopyranoside,	   D-­‐melibiose,	   D-­‐saccharose,	   inulin,	   D-­‐raffinose,	  
starch,	   glycogen,	   xylitol,	   D-­‐turanose,	   D-­‐lyxose,	   D-­‐fucose,	   D-­‐arabitol,	   L-­‐arabitol,	   2-­‐
ketogluconate	   or	   5-­‐ketogluconate.	   All	   fermented	   D-­‐arabinose,	   D-­‐ribose,	   D-­‐galactose,	   D-­‐
glucose,	   D-­‐mannitol,	   D-­‐fructose,	   D-­‐mannose,	   dulcitol,	   D-­‐sorbitol,	   N-­‐acetyl	   glucosamine,	  
amigdalin,	  arbutin,	  esculin,	  salicin,	  D-­‐cellobiose,	  D-­‐trehalose,	  D-­‐melezitose,	  gentiobiose,	  D-­‐
tagatose,	   L-­‐fucose	   and	   gluconate.	   All	   the	   putative	   L.	   rhamnosus	   isolates	   showed	   identical	  
sugar	  fermentation	  profiles,	  being	  different	  from	  those	  of	  the	  reference	  strain	  OL,	  which	  in	  
addition	   was	   able	   to	   ferment	   L-­‐sorbose,	   L-­‐rhamnose,	   Methyl-­‐αD-­‐glucopyranoside,	   D-­‐
maltose	  and	  D-­‐lactose.	  
	  
Tolerance	  to	  acidic	  pH	  (pH	  2	  and	  2.5)	  varied	  from	  43.0%	  to	  79.1%	  and	  showed	  no	  significant	  









Adhesion	  of	  L.	  rhamnosus	  isolates	  to	  human	  colonic	  mucus	  
	  
The	  adherence	  of	  L.	   rhamnosus	   isolates	  varied	  between	  different	   isolates	   (IV).	  That	  of	   the	  
original	   L.	   rhamnosus	   GG	  was	   19%	  ±	   7.5;	   that	   of	   the	   other	   isolates	   varied	   from	  12.1%	   to	  
24.3%.	  Only	  the	  adhesion	  of	   the	  reference	  strain	  OL	  differed	  significantly	   from	  that	  of	   the	  
original	   L.	   rhamnosus	   GG	   (p=0.01)	   and	   it	   also	   showed	   the	   lowest	   percentage	   of	   adhesion	  
among	  all	  isolates	  tested	  (data	  not	  shown).	  
	  
The	   pathogenic	   strains	   tested	   adhered	   as	   follows:	   S.	   aureus	   (10.2%	   ±	   3.0),	  C.	   perfringens	  
(4.0%	  ±	  3.1),	  S.	  enterica	  serovar	  Typhimurium	  (2.4%	  ±	  0.7),	  C.	  sakazakii	  (2.0%	  ±	  0.7).	  
	  
Properties	   of	   pathogen	   exclusion	   by	   L.	   rhamnosus	   isolates	   as	   compared	   to	   the	   original	  
Lactobacillus	  rhamnosus	  GG	  
	  
In	   exclusion	   by	   inhibition	   adherent	   bacteria	   block	   the	   adhesion	   of	   other	   bacteria	   to	   the	  
mucus.	   In	  this	  study	  (IV)	   the	  ability	  of	   the	  L.	   rhamnosus	   isolates	  to	   inhibit	   the	  adhesion	  of	  
pathogens	  to	  the	  colonic	  mucus	  differed	  significantly	  (Figure	  10).	  The	  original	  L.	  rhamnosus	  
GG	  was	  able	  to	  inhibit	  all	  pathogens	  tested	  and	  this	  microorganism	  reduced	  the	  adhesion	  of	  
C.	   sakazakii	   a	   31%,	   S.	   enterica	   serovar	   Typhimurium	   a	   25%,	   C.	   perfringens	   (25%)	   and	   S.	  
aureus	   	   (24%).	  Differences	  were	  seen	  between	  L.	  rhamnosus	   isolates	   in	  the	  adhesion	  of	  C.	  
sakazakii,	  S.	  enterica	  serovar	  Typhimurium	  and	  C.	  perfringens	  (p<0.001	  for	  each)	  but	  not	  S.	  
aureus	   (p=0.352).	   Four	   L.	   rhamnosus	   isolates	   (AL,	   LL,	  ML,	   NL)	   showed	   different	   inhibition	  
(p=0.083,	  p=0.015,	  p<0.001,	  p=0.025,	  respectively)	  of	  C.	  sakazakii	  compared	  to	  the	  original	  
L.	  rhamnosus	  GG.	  The	   isolate	  ML,	  again,	  differed	  (p<0.001)	  from	  the	  original	  L.	  rhamnosus	  
GG	   in	   inhibition	   of	   the	   adhesion	   of	   S.	   enterica	   serovar	   Typhimurium.	   Two	   L.	   rhamnosus	  
isolates	   (ML,	  OL)	   differed	   (p<0.001,	   p=0.032,	   respectively)	   from	   the	   original	   L.	   rhamnosus	  
GG	  in	  inhibiting	  the	  adhesion	  of	  C.	  perfringens.	  The	  adhesion	  inhibition	  of	  S.	  aureus	  did	  not	  
differ	  between	  the	  tested	  L.	  rhamnosus	  isolates	  and	  the	  original	  L.	  rhamnosus	  GG.	  
	  
In	   exclusion	   by	   displacement	   the	   adherent	   microorganisms	   are	   outnumbered	   by	   other	  
microbes.	  In	  this	  experiment	  (IV)	  all	  the	  L.	  rhamnosus	  isolates	  were	  able	  to	  displace	  the	  pre-­‐





rhamnosus	   isolates	   in	   the	   adhesion	   of	   C.	   sakazakii,	   S.	   enterica	   serovar	   Typhimurium	  
(p=0.063,	   p=0.001,	   respectively)	   but	   not	   between	   C.	   perfringens	   and	   S.	   aureus	   (p=0.128,	  
p=0.717,	  respectively).	  The	  original	  L.	   rhamnosus	  GG	  displaced	  54%	  of	  adhered	  S.	  enterica	  
serovar	   Typhimurium	   and	   it	   differed	   (p=0.084)	   from	   the	   L.	   rhamnosus	   LL	   isolate.	   C.	  
perfringens	  was	  displaced	  33%	  and	  S.	  aureus	  20%	  by	  the	  original	  L.	  rhamnosus	  GG;	  all	  other	  
isolates	  showed	  no	  difference	  in	  the	  displacement	  from	  the	  original	  L.	  rhamnosus	  GG.	  The	  
original	   L.	   rhamnosus	   GG	   displaced	   C.	   sakazakii	   by	   12%,	   differing	   (p=0.082,	   p=0.009,	  
p=0.017,	  p=0.013,	  p=0.068,	  p=0.019,	  p=0.01,	  p=0.092,	  p=0.051,	  respectively)	  from	  the	  other	  
study	  isolates	  AL,	  BL,	  CL,	  DL,	  EL,	  HL,	  IL,	  KL	  and	  NL.	  The	  results	  are	  shown	  in	  Figure	  11.	  
	  
	  
Figure	  10.	  Inhibition	  of	  the	  adhesion	  to	  the	  colonic	  mucus	  of	  pathogenic	  bacteria	  by	  the	  tested	  L.	  rhamnosus	  
isolates.	   Results	   are	   expressed	   as	   percentages	   with	   regard	   to	   the	   inhibition	   obtained	   with	   the	   original	   L.	  
rhamnosus	   GG	   isolate	   donated	   by	   Prof.	   S.	   Gorbach.	   Values	   on	   the	   X-­‐axis	   higher	   than	   0	   indicate	   adhesion	  
inhibition	  higher	  than	  the	  original	  L.	  rhamnosus	  GG	  and	  those	  lower	  than	  0	  indicate	  adhesion	  inhibition	  lower	  
than	   the	   original	   L.	   rhamnosus	   GG.	   Asterisks	   indicate	   adhesion	   significantly	   different	   from	   the	   original	   L.	  
rhamnosus	  GG	   (*	   if	   0.05≤	  p<0.10	  and	  **	   if	   p<0.05).	  Values	  are	  means,	  with	   standard	  errors	   represented	  by	  






In	   exclusion	   by	   competition	  microorganisms	   compete	   for	   adherence	   at	   the	   same	   time.	   In	  
this	   work	   (IV)	   the	   inhibition	   by	   competition	   varied	   among	   L.	   rhamnosus	   isolates	   and	  
pathogens	  tested.	  The	  relevant	  data	  are	  shown	  in	  Figure	  12.	  The	  presence	  of	  some	  isolates	  
increased	  the	  adhesion	  of	  C	  sakazakii,	  S.	  enterica	  serovar	  Typhimurium	  and	  C.	  perfringens	  to	  
the	  colonic	  mucus.	  All	  but	  one	  isolate	  –	  BL	  were	  able	  to	  reduce	  the	  adhesion	  of	  S.	  aureus.	  
Differences	  were	  noted	  between	   L.	   rhamnosus	   isolates	   in	   the	   adhesion	  of	  C.	   sakazakii,	   S.	  
enterica	   serovar	   Typhimurium,	   C.	   perfringens	   and	   S.	   aureus	   (p<0.001,	   p<0.001,	   p=0.005,	  
p=0.023,	  respectively).	  	  
	  
	  
Figure	  11.	  Displacement	  of	  adhesion	  to	  the	  colonic	  mucus	  of	  pathogenic	  bacteria	  by	  the	  tested	  L.	  rhamnosus	  
isolates.	  Results	  are	  expressed	  as	  percentages	  with	   regard	   to	   the	  displacement	  obtained	  with	   the	  original	  L.	  
rhamnosus	   GG	   isolate	   donated	   by	   Prof.	   S.	   Gorbach.	   Values	   on	   the	   X-­‐axis	   higher	   than	   0	   indicate	   adhesion	  
displacement	  higher	  than	  the	  original	  L.	  rhamnosus	  GG	  and	  those	  lower	  than	  0	  displacement	   lower	  than	  the	  
original	  L.	  rhamnosus	  GG.	  Asterisks	   indicate	  adhesion	  displacement	  significantly	  different	  from	  the	  original	  L.	  
rhamnosus	  GG	   (*	   if	   0.05≤	  p<0.10	  and	  **	   if	   p<0.05).	  Values	  are	  means,	  with	   standard	  errors	   represented	  by	  







The	   original	   L.	   rhamnosus	   GG	   showed	   inhibition	   abilities	   for	   all	   pathogens	   tested.	   This	  
microorganism	   inhibited	   the	   adhesion	   of	  C.	   perfringens	   in	   47%,	   being	   different	   (p=0.057,	  
p=0.059,	  p=0.07,	  p=0.091,	  respectively)	  from	  BL,	  LL,	  ML,	  NL	  isolates;	  S.	  aureus	  in	  39%,	  being	  
different	   (p=0.019)	   from	   BL	   isolate;	   S.	   enterica	   serovar	   Typhimurium	   5%,	   being	   different	  
(p=0.064,	   p=0.014,	   p=0.026,	   respectively)	   from	   IL,	   ML,	   NL	   isolates;	   and	   C.	   sakazakii	   9%,	  
showing	  a	  difference	  (p=0.001,	  p=0.003,	  p=0.048,	  p=0.001,	  p<0.001,	  p=0.079,	  respectively)	  
from	  AL,	  DL,	  LL,	  ML,	  NL	  isolates	  and	  the	  reference	  strain	  OL.	  
	  
	  
Figure	  12.	  Competition	  for	  adhesion	  to	  the	  colonic	  mucus	  of	  pathogenic	  bacteria	  by	  the	  tested	  L.	  rhamnosus	  
isolates.	   Results	   are	   expressed	   as	   percentages	  with	   regard	   to	   the	   competition	   obtained	  with	   the	   original	   L.	  
rhamnosus	   GG	   isolate	   donated	   by	   Prof.	   S.	   Gorbach.	   Values	   on	   the	   X-­‐axis	   higher	   than	   0	   indicate	   adhesion	  
competition	   higher	   than	   the	   original	   L.	   rhamnosus	   GG	   and	   those	   lower	   than	   0	   competition	   lower	   than	   the	  
original	  L.	   rhamnosus	  GG.	  Asterisks	   indicate	   adhesion	   competition	   significantly	  different	   from	   the	  original	  L.	  
rhamnosus	  GG	   (*	   if	   0.05≤	  p<0.10	  and	  **	   if	   p<0.05).	  Values	  are	  means,	  with	   standard	  errors	   represented	  by	  











6.1	  Factors	  influencing	  gut	  microbiota	  composition	  in	  infants	  
	  
The	   association	   between	   mother	   and	   infant	   gut	   microbiota	   during	   early	   life	   has	   been	  
reported	   to	   be	   a	   critical	   factor	   for	   the	   subsequent	   succession	   of	   intestinal	   commensal	  
bacteria	   in	   infancy	   (Grönlund	   et	   al.	   1999,	   Adlerberth	   et	   al.	   2006,	   Adlerberth	   et	   al.	   2007).	  
During	  the	  perinatal	  period	  an	  actual	  transmission	  of	  gut	  bacteria	  from	  mother	  to	  infant	  has	  
been	  detected	   (Tannock	  et	  al.	  1990,	  Murono	  et	  al.	  1993).	   In	   the	  gut	  of	  healthy	  breast-­‐fed	  
infants,	   bifidobacteria	   are	   already	   the	   predominant	   bacterial	   group	   at	   3	   days	   of	   age	   and	  
they	  continue	  to	  predominate	  during	  the	  first	  6	  months	  of	  life	  (Harmsen	  et	  al.	  2000,	  Favier	  
et	  al.	  2002,	  Studies	  I,	  II,	  III,	  A).	  In	  Study	  I,	  a	  significant	  correlation	  in	  levels	  of	  Bifidobacterium	  
in	  mothers	  and	  infants	  was	  observed	  at	  1	  month	  after	  delivery.	  In	  contrast,	  previous	  studies	  
have	  found	  no	  correlation	   in	  faecal	  total	  counts	  of	  bifidobacteria	  between	  mothers	  and	  1-­‐
month-­‐old	  infants	  (Grönlund	  et	  al.	  2007,	  Mikami	  et	  al.	  2009).	  However,	  in	  the	  present	  case	  
almost	   all	   infants	   were	   exclusively	   breast-­‐fed	   and	   thus	   the	   bifidobacteria	   found	   in	  
breastmilk	   could	   have	   impacted	   on	   the	   association	   detected.	   Additionally,	   the	   DI	   of	  
bifidobacteria	   in	   infants	   and	   mothers	   here	   correlated	   at	   1	   month	   after	   delivery.	  
Furthermore,	   the	   infants	  who	  harboured	  diverse	  bifidobacterial	  microbiota	  at	  1	  month	  of	  
age	  tended	  to	  do	  so	  also	  later	  on	  in	  infancy,	  since	  the	  bifidobacterial	  DI	  in	  infants	  at	  1	  and	  6	  
months	   of	   age	   correlated.	   These	   findings	   thus	   emphasise	   the	   importance	   of	   the	   gut	  
microbiota	  association	  between	  mother	  and	  infant	  in	  early	  infancy.	  A	  constant	  association	  in	  
the	  colonisation	   rates	  of	  B.	  bifidum	   in	   the	  mother-­‐infant	  pairs	  was	  detected	  both	  1	  and	  6	  
months	   after	   delivery.	   The	   colonisation	   rates	   of	  B.	   breve	   correlated	   in	   the	  mother-­‐infant	  
pairs	  only	  at	  1	  month	  after	  delivery.	  On	  the	  other	  hand,	  no	  correlation	  in	  colonisation	  rates	  
between	  mothers	  and	   infants	   could	  be	   found	   in	  other	  bifidobacterial	   species	  assessed	   (B.	  
catenulatum,	  B.	  lactis,	  B.	  infantis,	  B.	  adolescentis).	  These	  findings	  suggest	  that	  colonisation	  
of	   infants	   by	  B.	   bifidum	   is	  more	   depedent	   on	   the	  mother-­‐infant	   association	   compared	   to	  
other	  bifidobacterial	   species.	  Along	  with	  B.	   longum,	  B.	   infantis	   and	  B.	  breve,	  B.	  bifidum	   is	  
also	  one	  of	  the	  predominating	  bifidobacterial	  species	  residing	  in	  the	  infant	  gut	  (Harmsen	  et	  
al.	   2008,	   Matsuki	   et	   al.	   1999,	   He	   et	   al.	   2001b,	   Rinne	   et	   al.	   2005,	   Grönlund	   et	   al.	   2007,	  





which	   increased	   the	   DI	   of	   bifidobacteria	   in	   the	   faeces	   of	   infants	   and	   the	   mother-­‐infant	  
bifidobacterial	  SI	  at	  both	  1	  and	  6	  months	  of	  age,	  while	  in	  the	  study	  by	  Mikami	  and	  associates	  
(2009)	   B.	   breve	   increased	   both	   the	   bifidobacterial	   counts	   and	   the	   diversity	   of	  
Bifidobacterium	  species	  in	  infant	  faeces	  at	  1	  month	  of	  age.	  Thus,	  factors	  which	  contribute	  to	  
the	  diversity	  of	  the	  intestinal	  microbiota	  should	  be	  further	  elucidated,	  since	  diversity	  in	  the	  
intestinal	  microbiota	   in	  early	   life	  has	  been	  claimed	   to	  be	  one	   important	   factor	  preventing	  
the	  development	  of	  atopic	  diseases	  (Wang	  et	  al.	  2008).	  	  
It	   is	  tempting	  to	  speculate	  that	  those	  bifidobacteria	  which	  correlate	  between	  mothers	  and	  
infants	   are	   the	   important	   ones	   for	   the	   later	   health	   of	   the	   infants.	   Evolutionary	   vaginal	  
delivery	  was	  the	  means	  of	  ensuring	  that	  maternal	  intestinal	  bacteria	  were	  transferred	  to	  the	  
newborn.	   The	   findings	   here	   show	   that	   there	   is	   a	   significant	   correlation	   in	   the	   intestinal	  
bifidobacterial	  microbiota	   between	  mothers	   and	   infants	   and	   that	  B.	   bifidum	   and	  B.	   breve	  
constitute	   such	   maternal	   bifidobacterial	   species	   which	   might	   modulate	   the	   colonisation	  
process	  in	  the	  newborns	  more	  markedly	  than	  others.	  
	  
In	   addition	   to	   the	   mother’s	   own	   microbiota,	   it	   has	   also	   been	   suggested	   that	   sanitation,	  
hygiene	   and	   environment	   may	   guide	   the	   succession	   of	   microbes	   (Adlerberth	   and	   Wold	  
2009,	  Favier	  et	  al.	  2002,	  Palmer	  et	  al.	  2007).	  Distinct	  gut	  microbiota	  compositions	  in	  infants	  
from	   different	   geographic	   areas	   have	   been	   reported	   (Adlerberth	   et	   al.	   1991),	   as	   well	   as	  
across	  Europe	  (Björkstén	  et	  al.	  1999,	  Fallani	  et	  al.	  2010,	  Sepp	  et	  al.	  1997)	  and	  in	  Europe	  and	  
Africa	  (De	  Filippo	  et	  al.	  2010)	  respectively.	  
In	   this	   series	   of	   studies	   comparison	  was	  made	   between	   the	  microbiota	   of	   South	   Eastern	  
African	   with	   Northern	   European	   infants	   (II)	   and	   across	   European	   infants	   (III).	   The	   gut	  
microbiota	   of	   Malawian	   infants	   showed	   an	   abundance	   of	   Bifidobacterium,	   Bacteroides-­‐
Prevotella	   and	   Clostridium	   histolyticum	   as	   compared	   to	   the	   levels	   of	   these	   bacteria	   in	  
Finnish	   infants	   (II).	   In	   contrast,	   in	   a	   study	   comparing	   gut	   microbiota	   in	   infants	   from	   two	  
European	  cohorts	  (III),	  higher	  counts	  of	  Clostridium	  histolyticum	  and	  Bacteroides-­‐Prevotella	  
were	   observed	   in	   German	   as	   compared	   to	   Finnish	   breast-­‐fed	   infants.	   The	   most	   likely	  
explanation	   for	   the	  effect	  seen	   in	  African	   infants	   is	   the	  diet,	   this	  being	  composed	  of	  plant	  
polysaccharides,	  which	   are	   introduced	   together	  with	   breast-­‐feeding	   already	   in	   infancy.	   In	  
recent	  studies	  by	  Ley	  and	  collaborators	  (2005,2006),	  a	  high	  Firmicutes	  /	  Bacteroidetes	  ratio	  





weight	   loss.	   These	   previous	   results	   are	   in	   accord	   with	   the	   difference	   observed	   in	   the	  
numbers	  of	  Bacteroidetes	  coinciding	  with	  weight	  differences	  between	  Malawian	  and	  infants	  
from	  south-­‐western	  Finland,	  whether	  related	  or	  unrelated	  to	  the	  diet	  (II).	  In	  recent	  studies	  
from	   Finland,	   again,	   higher	   levels	   of	   Bacteroidetes,	   clostridial	   species	   and	   staphylococci	  
were	  seen	  in	  obese	  and	  overweight	  infants	  and	  adults	  (Collado	  et	  al.	  2010,	  Kalliomäki	  et	  al.	  
2008)	  while	  at	  the	  same	  time	  Bacteroidetes	   levels	  were	  significantly	  higher	   in	   infants	  from	  
obese	  mothers	  during	  the	  first	  6	  months	  of	  life	  (Collado	  et	  al.	  2010).	  In	  addition,	  Malawian	  
infants	   were	   less	   often	   colonised	   with	   specific	   clostridial	   species	   and	   staphylococci	   (II).	  
Bacteroides	   and	   specific	   Clostridium	   species	   such	   as	   those	   found	   in	   Finnish	   and	   German	  
infants	   (II,	   III,	   A)	  may	   often	   be	   considered	   as	   opportunistic	   pathogens,	   but	   they	   are	   also	  
commonly	   isolated	   from	   infant	   faeces	  and	  are	   regarded	  as	   indicators	  of	  healthy	  microbial	  
gut	  succession	  (Stark	  and	  Lee	  1982,	  Wexler	  2007,	  Tonooka	  et	  al.	  2005).	  
	  
Bifidobacteria	  have	  been	  seen	  to	  typify	  the	  gut	  microbiota	  of	  healthy	  breast-­‐fed	  infants.	  This	  
appears	   to	   be	   the	   case	   in	   the	   populations	   studied	   here	   (II,	   III,	   A).	   High	   levels	   of	  
bifidobacteria	   in	   breast-­‐fed	   infants	   have	   previously	   been	   reported,	   and	   this	   may	   reflect	  
breast-­‐feeding	  practices	  i.e.	  length	  of	  breast-­‐feeding	  or	  exclusive	  breast-­‐feeding,	  as	  well	  as	  
the	   impact	  of	   the	  environment	   (Rinne	  et	  al.	  2005,	  Grönlund	  et	  al.	  2007).	  A	  more	  detailed	  
breakdown	   of	   species	   composition	   reveals	   species	   differences	   among	   subpopulations	   of	  
infants	  (Gueimonde	  et	  al.	  2007,	  Ouwehand	  et	  al.	  2001c).	  Such	  findings	  might	  be	  associated	  
with	  the	  different	  immunomodulatory	  properties	  of	  specific	  bifidobacterial	  species	  present	  
in	   the	   gut.	   In	   particular,	   B.	   adolescentis	   has	   been	   associated	   with	   inflammatory	   effects,	  
while	  B.	  longum	  and	  B.	  bifidum	  have	  been	  shown	  to	  possess	  immunomodulatory	  properties	  
(Collado	  et	  al.	  2008,	  Isolauri	  et	  al.	  2002).	  Interestingly,	  B.	  adolescentis	  was	  detectable	  only	  in	  
Finnish	   infants	   and	   B.	   catenulatum	   in	   both	   groups	   (II).	   In	   Malawian	   (II)	   and	   Finnish	   (III)	  
infants	  	  the	  prominent	  species	  were	  B.	  longum,	  B.	  bifidum	  and	  B.	  breve.	  Thus,	  the	  potential	  
role	  of	  Bifidobacterium	  species	  composition	  and	  the	  quantity	  of	  total	  microbiota	  in	  infants	  in	  
high-­‐income	   countries	   may	   be	   more	   marked,	   favouring	   the	   allergy	   risk.	   In	   low-­‐income	  
countries	  such	  as	  Malawi,	  the	  situation	  may	  be	  the	  opposite,	  providing	  clues	  for	  measures	  
preventive	  of	  the	  trend	  in	  high-­‐income	  areas.	  
	  





Akkermansia-­‐like	   bacteria,	   which	   were	   abundant	   in	   the	   Finnish	   infants.	   In	   contrast,	   the	  
findings	   from	   study	   III	   characterising	   the	   German	   breast-­‐fed	   infant	   population	  
demonstrated	   that	   the	   gut	   microbiota	   is	   more	   complex	   and	   contains	   significantly	   higher	  
counts	  and	  percentages	  of	  Akkermansia	  muciniphila	  when	  compared	  to	  Finnish	  breast-­‐fed	  
infants.	   A.	   muciniphila	   has	   been	   shown	   to	   be	   a	   common	   member	   of	   the	   infant	   gut	  
microbiota	   in	   Europe,	   typically	   beginning	   to	   colonise	   the	   intestine	   early	   in	   infancy	   and	  
increasing	   in	   numbers	   again	   towards	   adulthood	   (Collado	   et	   al.	   2007a).	   It	   has	   also	   been	  
shown	   that	   Akkermansia	   can	   degrade	   the	   intestinal	   mucus,	   as	   this	   bacterium	   contains	  
numerous	  candidate	  mucinase-­‐encoding	  genes	  (Passel	  et	  al.	  2011).	  The	  mucus	  degradation	  
caused	   by	  Akkermansia	   may	   affect	   the	   innate	   and	   adaptive	   immune	   responses	   in	   that	   it	  
disturbs	  the	  first-­‐defence	  protection	  of	  the	  host	  mucosal	  surfaces.	  This	  would	  suggest	  that	  
Akkermansia	   may	   have	   a	   role	   in	   the	   pathogenesis	   of	   inflammatory	   diseases	   (Shih	   et	   al.	  
2008)	  and	  even	  obesity	  (Kalliomäki	  et	  al.	  2008,	  Collado	  et	  al.	  2008,	  Collado	  et	  al.	  2010).	  The	  
absence	  of	  Akkermansia-­‐like	  bacteria	  in	  Malawian	  infants	  could	  thus	  constitute	  a	  protective	  
health	   factor	   against	   westernised	   diseases	   (II).	   This,	   together	   with	   the	   observation	   that	  
Akkermansia	  muciniphila	  was	  more	  often	  detected	   in	  Finnish	   (II)	  and	  German	   infants	   (III),	  
would	  suggest	  a	  role	  for	  this	  species	  as	  a	  marker	  organism	  for	  gut	  microbiota	  development	  
and	  diversity.	  	  
	  
The	   specific	   microbiota	   composition	   found	   in	   Malawian	   infants	   may	   constitute	   a	   barrier	  
against	   some	   potentially	   pathogenic	   intestinal	   microbes	   constantly	   challenging	   infants	   in	  
low-­‐income	  areas	  with	  poor	  hygiene.	  A	  recent	  study	  from	  the	  Ivory	  Coast	  (Zimmermann	  et	  
al.	  2010)	  reported	  that	  anaemic	  African	  children	  carry	  an	  unfavourably	  high	  ratio	  of	  faecal	  
enterobacteria	   to	   bifidobacteria	   and	   lactobacilli.	   This	   ratio	   is	   further	   increased	   by	   iron	  
fortification.	   Thus,	   the	   specific	   microbiota	   composition	   in	   Malawian	   infants	   could	   be	  










6.2 Gut	   microbiota	   modulation	   by	   probiotics	   in	   infants	   and	   probiotic	   product	   quality	  
measurement	  
	  
Probiotics	  are	  nonpathogenic,	  viable	  microbes	  which	  exert	  a	  variety	  of	  beneficial	  effects	  on	  
the	  host	  when	  consumed	  in	  adequate	  amounts	  (FAO/WHO	  2002).	  Administration	  of	  specific	  
probiotics	  perinatally	  and	  during	  the	  first	  months	  of	  life,	  but	  also	  the	  pre-­‐existing	  microbiota	  
and	   the	   environment,	  may	   have	   a	   long-­‐term	  beneficial	   influence	   on	   the	   composition	   and	  
development	   of	   the	   infant’s	  microbial	   ecosystem,	   potentially	   leading	   to	   a	   reduced	   risk	   of	  
diseases	  (Isolauri	  et	  al.	  2001,	  Kalliomäki	  et	  al.	  2001b).	  
	  
When	   analysing	   the	   gut	   microbiota	   of	   Finnish	   breast-­‐fed	   infants	   (III)	   whose	   mothers	  
received	  the	  specific	  probiotic	  combination	  LPR+BL999,	  it	  was	  found	  that	  the	  percentages	  of	  
Lactobacillus-­‐Enterococcus	  in	  the	  total	  count	  of	  bacteria	  were	  significantly	  higher	  compared	  
to	   those	   in	   placebo	   infants.	   The	   finding	   confirms	   that	   oral	   administration	   of	   a	   specific	  
probiotic	  to	  the	  mother,	  for	  example	  the	  combination	  with	  Lactobacillus	  rhamnosus	  LPR	  and	  
Bifidobacterium	   longum	  BL999,	  promotes	   the	  growth	  of	   lactic	  acid	  bacteria	   in	   the	   infant’s	  
gut,	   and	   that	   the	   impact	   is	   still	   in	   evidence	   4	   months	   after	   discontinuation	   of	   probiotic	  
administration.	  	  
In	   contrast,	   species	   identification	   suggests	   that	   the	   LPR+BL999	   combination	   lowered	   the	  
numbers	  of	  bifidobacteria	   compared	   to	   the	  placebo	  group	  and	   the	  colonisation	   rate	  of	  B.	  
infantis	   was	   lower	   than	   in	   other	   intervention	   study	   groups.	   In	   a	   recent	   report	   on	  
Lactobacillus	   rhamnosus	   GG	   administered	   to	   mothers	   4	   weeks	   before	   delivery,	   the	  
colonisation	   rate	   of	  B.	   longum	   in	   3-­‐month-­‐old	   infants	   was	   lower	   as	   compared	   to	   that	   in	  
placebo-­‐treated	   infants	   (Lahtinen	   et	   al.	   2009).	   This	   notwithstanding,	   in	   a	   previous	   study	  
from	  our	  group	  Lactobacillus	  rhamnosus	  GG	  had	  the	  effect	  of	  raising	  the	  colonisation	  rate	  of	  
B.	  breve	  and	  lowering	  that	  of	  B.	  adolescentis	  at	  5	  days	  of	  age,	  but	  no	  longer	  at	  3	  weeks	  of	  
age	   (Gueimonde	   et	   al.	   2006).	   Both	   studies,	  where	   LGG	  was	   administered	   via	   the	  mother,	  
show	  that	  Lactobacillus	  rhamnosus	  intervention	  might	  affect	  the	  bifidobacterial	  colonisation	  
process	  in	  infancy.	  Nonetheless,	  the	  effects	  at	  species	  level	  may	  be	  related	  to	  age,	  feeding	  
regimen	  and	  country.	  In	  contrast,	  the	  probiotic	  combination	  ST11+BL999	  had	  only	  a	  minor	  






The	   specific	   probiotic	   combinations	   administered	   to	   formula-­‐fed	   German	   infants	   (III)	   had	  
only	   minor	   effects	   on	   microbiota	   composition.	   The	   LPR+BL999	   treatment	   affected	   the	  
bifidobacterial	   composition	   by	   apparently	   lowering	   the	   bacterial	   counts	   of	   B.	   bifidum	  
compared	   to	   the	   placebo	   group.	   The	   species	   B.	   bifidum	   is	   commonly	   isolated	   from	   the	  
faeces	  of	  healthy	  infants	  and	  adults.	  Together	  with	  other	  bifidobacteria,	  B.	  bifidum	  plays	  an	  
important	   role	   in	   intestinal	   homeostasis	   and	   strengthens	   gastrointestinal	   immunity	  
especially	   in	  children	   (Lin	  et	  al.	  2008).	  The	  effects	  of	  probiotic	   intervention	   in	   the	  German	  
population	   were	   less	   evident	   than	   in	   the	   Finnish,	   this	   possibly	   depending	   on	   feeding	  
practice.	   In	  the	  more	  complex	  intestinal	  microbiota	  of	  the	  German	  formula-­‐fed	  infants	  the	  
effects	   remained	   fairly	   small,	  and	   for	  example	  no	  effects	  on	   lactobacilli	   contents	  could	  be	  
found.	  
	  
One	   further	   cause	   of	   variation	   in	   the	   outcomes	   of	   clinical	   studies,	   beyond	   differences	   in	  
populations,	   selection	   criteria	   and	   study	   design,	   may	   arise	   when	   different	   production	  
conditions,	  growth	  media,	  drying	  conditions	  or	  cryoprotectants	  are	  used	  for	  the	  same	  strain	  
or	  when	  a	  successful	  probiotic	  is	  combined	  with	  other	  bacteria	  or	  strains.	  For	  example,	  no	  
clinical	  and	  immunological	  effects	  were	  achieved	  when	  L.	  rhamnosus	  GG	  was	  combined	  with	  
L.	  rhamnosus	  LC705,	  Bifidobacterium	  breve	  Bb99	  and	  Propionibacterium	  freudenreichii	  ssp.	  
shermanii	  (Kukkonen	  et	  al.	  2008).	  In	  addition,	  the	  adhesion	  properties	  of	  the	  L.	  rhamnosus	  
GG	   strain	   (ATCC	   53103)	   have	   been	   shown	   to	   depend	   on	   the	   composition	   of	   the	   growth	  
media	   and	   the	   number	   of	   starter	   culture	   transfers	   (Elo	   et	   al.	   1991).	   Scientifically	   it	   is	   not	  
surprising	   that	   different	   microorganisms	   have	   different	   effects.	   Though	   Lactobacillus	  
rhamnosus	   GG	   is	   one	   of	   the	   probiotics	   subjected	   to	   the	   largest	   numbers	   of	   human	  
intervention	  studies,	  in	  many	  cases	  no	  attention	  has	  been	  paid	  to	  the	  specific	  properties	  of	  
the	  strains	  used.	  
Adherence	  of	  bacteria	  to	  the	   intestinal	  mucus	  or	  epithelium	  is	  known	  to	  be	  a	  prerequisite	  
for	   colonisation	  and	   infection	  of	   the	   gastrointestinal	   tract	  by	  many	  pathogens	   (Finlay	   and	  
Falkow	   1997).	   The	   adherent	   probiotic	   strains	   may	   at	   least	   temporarily	   colonise	   the	  
gastrointestinal	   tract	   and	   inhibit	   or	   compete	   with	   pathogens	   (Vesterlund	   et	   al.	   2006).	  
Several	   reports	   have	   described	   the	   adhesion	   abilities	   of	   probiotic	   strains	   and	   also	   their	  
inhibitory	   effects	   on	   model	   pathogen	   adhesion	   to	   the	   human	   mucus	   (Ouwehand	   et	   al.	  





isolates	  showed	  the	  ability	  to	  adhere	  to	  the	  human	  colonic	  mucus	  and	  while	  the	  adhesion	  
ability	   of	   different	   isolates	   varied	   it	   did	   not	   differ	   significantly.	   However,	   the	   model	  
pathogen	  exclusion	   results	   varied	   significantly	   and	  depended	  on	   the	   isolate	   tested.	   These	  
findings	   would	   indicate	   differences	   in	   these	   important	   properties	   of	   probiotics	   among	  
different	   L.	   rhamnosus	   isolates	   obtained	   from	   different	   sources.	   They	   suggest	   that	   the	   in	  
vitro	  properties	  of	  probiotics	  may	  vary	  depending	  on	  the	  production	  conditions	  used	  for	  the	  
same	  strain.	  	  
The	  findings	  in	  this	  series	  (IV)	  indicate	  that	  different	  isolates	  of	  the	  same	  strain	  may	  possess	  
different	   properties,	   which	   may	   influence	   their	   in	   vivo	   effects,	   underlining	   the	   need	   to	  
control	  the	  manufacturing	  process	  and	  the	  food	  matrix.	  The	  L.	  rhamnosus	  isolates	  tested	  in	  
this	   study	   were	   chosen	   to	   represent	   different	   products	   and	   origins.	   The	   manufacturing	  
process	  may	  thus	  have	  had	  a	  significant	  impact	  on	  the	  strain	  properties.	  Often	  probiotics	  are	  
used	  in	  fermented	  dairy	  products	  or	  as	  freeze-­‐dried	  preparations.	  Both	  provide	  a	  matrix	  for	  
the	  microorganisms	  and	  previous	  studies	  have	   indicated	  that	  the	  matrix	  may	  affect	  strain-­‐
specific	   properties	   (Kankaanpää	   et	   al.	   2001,2004).	   This,	   along	   with	   the	   production	  
conditions,	  may	  in	  part	  explain	  the	  divergent	  results	  obtained	  between	  strain	  isolates	  when	  
characterising	   strain	   impact	   on	   pathogen	   adhesion	   to	   the	   mucus.	   Variations	   in	   these	  
properties	  may	  have	  a	  different	  impact	  on	  gut	  microbiota	  modulation	  in	  individual	  subjects,	  
which	   can	  partially	  explain	   the	  probiotic	  effect	   seen	   in	   studies	   I	   and	   III.	   They	  may	   further	  

















7.	  SUMMARY	  AND	  CONCLUSIONS	  
	  
The	  results	  of	  this	  present	  series	  suggest	  that	  the	  gut	  microbiota	  of	  6-­‐month-­‐old	  European	  
and	  African	  infants	  is	  dominated	  mainly	  by	  bifidobacteria.	  They	  further	  reveal	  that	  specific	  
Bifidobacterium	  species	  might	  be	  present	  for	  their	  health-­‐promoting	  role	  in	  different	  areas	  
of	  the	  world.	  	  
The	   findings	   are	   supported	   by	   the	   clear	   association	   seen	   between	   the	   mother	   and	   the	  
infant,	   reflected	   in	   gut	   colonisation	  by	  bifidobacteria,	   especially	   by	   the	   species	  B.	   bifidum	  
and	  B.	  breve,	  of	  which	  the	  two	  latter	  are	  evidently	  important	  for	  the	  subsequent	  health	  of	  
the	  infant.	  
Geographical	   differences	   in	   microbiota	   composition	   are	   observed	   in	   the	   appearance	   of	  
Bifidobacterium,	  Bacteroides,	  Clostridium	  and	  Akkermansia	   in	  6-­‐month-­‐old	   infants	  and	  this	  
may	  have	  been	  guided	  by	   initial	  environmental	  exposures,	   including	  diet	  and	  hygiene.	  The	  
role	   of	   microbiota,	   diet	   and	   hygiene	   may	   thus	   be	   more	   prominent	   than	   expected	   in	  
providing	  protection	  against	  aberrancies	  and	  inflammatory	  challenges.	  
Probiotic	   administration	   to	  mothers	   has	   no	  major	   effect	   on	   the	  mother-­‐infant	  microbiota	  
interaction	   process.	   The	   gut	   microbiota	   ecosystem	   of	   the	   infant	   can	   be	   modulated	   by	  
specific	   probiotic	   treatments	   administered	   during	   the	   prenatal	   and	   perinatal	   period.	  
However,	  this	  process	  is	  dependent	  on	  both	  the	  mother’s	  and	  the	  infant’s	  own	  microbiota,	  
feeding	   practices,	   and	   the	   environment.	   Another	   possible	   reason	   for	   the	   differences	   in	  
outcomes	  of	  probiotic	  interventions	  in	  infants	  lies	  in	  the	  finding	  that	  the	  original	  properties	  
used	  in	  the	  selection	  of	  a	  specific	  probiotic	  strain	  may	  be	  influenced	  by	  industrial	  production	  
processes	   and	   conditions	   as	  well	   as	   by	   the	   food	  matrix	   used.	   This	   can	   lead	   to	   changes	   in	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